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Giardia lamblia is a non-invasive protozoan parasite, infecting mainly the upper small 
intestine. It is the most common cause of waterborne outbreaks of diarrhea in an 
endemic country.  
The first registered large outbreak of giardiasis in Bergen occurred Autumn 2004, 
where about 1262 subjects were diagnosed with Giardia lamblia and 139 continued to 
have abdominal symptoms, despite several treatments with metronidazole. A long-
term follow-up study from our group showed that a subgroup of these patients 
developed symptoms consistent with Giardia induced Post-Infectious Functional 
Gastrointestinal Disorder (PI-FGID).  
Aims 
This thesis aimed to study visceral sensitivity and low-grade inflammation, assessed 
by duodenal EC cells, serotonin (5-HT), cholecystokinin (CCK), T- and B-
lymphocytes in patients with long-term abdominal symptoms after Giardia infection.  
The most of PI-FGID patients had an overlap of FD and IBS.  
Methods 
In Paper I, gastric emptying and visceral sensitivity were assessed in PI-FD/IBS 
patients and recovered controls (RC) by using 3D ultrasonography (3D US) in 
combination with a low caloric soup meal. A subgroup of PI-FD/IBS patients 
underwent a double-blind, randomized, placebo-controlled study with 5-HT3 
antagonist (Ondansetron®) in combination with a low-caloric soup meal and 3D US.  
In Paper II, fasting and postprandial changes in plasma 5-HT and CCK after the 
carbohydrate-rich meal were assessed in PI-FD/IBS patients and RC. In addition, 




duodenal EC cells, 5-HT, CCK, mast cells and CgA were stained 
immunohistochemically (IHC) and quantified.   
In paper III, duodenal mucosal intraepithelial lymphocytes (IELs), lamina propria 
villus (Lpv) and lamina propria crypt (Lpc) for CD3+, CD4+, CD8+ and CD20+ 
lymphocytes were stained immunohistochemically (IHC) and quantified in chronic 
giardiasis (CG) patients, PI-FGID patients, recovered controls (RC) and healthy (non-
Giardia exposed) controls (HC). 
Results 
In Paper I, PI-IBS/FD patients had more abdominal symptoms as well as lower 
drinking capacity and increased visceral sensitivity. 
5-HT3 antagonist (Ondansetron®) had effect on postprandial nausea, otherwise there 
was no effect on other symptoms, drinking capacity or gastric emptying. 
In Paper II, only a few PI-FD/IBS patients had a sign of microscopical duodenal 
inflammation. When compared to recovered controls, patients had lower duodenal 5-
HIAA/5-HT ratio and reduced duodenal 5-HT containing EC cell counts. There was a 
positive correlation between duodenal EC cell numbers and mucosal 5-HT content in 
the PI-FD/IBS patients, who also had increased number of duodenal CCK containing 
cells with a greater CCK/5-HT ratio compared to recovered controls.  
After the carbohydrate-rich meal, PI-FD/IBS patients had lower fasting and 
postprandial plasma 5-HIAA, with a higher abdominal symptom score compared to 
RC. Plasma 5-HIAA showed no correlation to abdominal symptoms. CCK plasma 
levels did not differ between PI-IBS/FD and recovered group but showed positive 
correlation to fullness and bloating in PI-IBS/FD patients.  
 
In Paper III, duodenal IEL CD4 cells was significantly elevated in chronic giardiasis 
and then decreased, followed by an upwards trend after one year in both the PI-FGID 




and recovered control group. Duodenal lamina propria crypt CD4 T cells were lower 
in chronic giardiasis patients and remained low for about 14 months before 
normalizing. Duodenal lamina propria crypt (Lpc) CD20+ cells were persistently 
elevated, longer than 19 months, in all three Giardia exposed groups, compared to 
healthy controls.  
Conclusions 
Patients with persistent abdominal symptoms after cured Giardia infection, in whom 
most had overlap IBS and FD, had increased visceral sensitivity with lower drinking 
capacity and delayed gastric emptying assessed by the low-caloric soup test combined 
with 3D ultrasound. 
The 5-HT3 antagonist (Ondansetron®) improved only nausea without influencing 
other symptoms, drinking capacity or gastric emptying (Paper I).  
These patients had decreased number of 5-HT containing EC cells and increased 
number of duodenal CCK containing cells, with a greater CCK/5-HT ratio compared 
to recovered controls (Paper II). After intake of the carbohydrate-rich meal, PI-FGID 
patients had lower plasma 5-HT, before and after a meal, with more dyspepsia 
symptoms without significant differences in plasma CCK.  
The decreased number of duodenal CD4 cells in the lamina propria crypt, were found 
in chronic giardiasis and PI-FGID patients, but also recovered controls, and it 
normalized approximately 14 months after the acute illness, while elevated B cells in 
the crypts appeared to last longer than 19 months in all three Giardia exposed groups 
(Paper III).  
In PI-FGID group, duodenal EC cell counts (Paper II) were positively correlated to 
persisting low duodenal Lpv CD4 and Lpc CD4 cells (Paper III).  
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1. INTRODUCTION 
1.1. Giardia outbreak in Bergen and persistent abdominal symptoms after 
giardiasis  
A large waterborne outbreak of giardiasis, the first recognized parasite outbreak 
caused by drinking water occurred in Bergen, Norway in Autumn 2004. The patients 




were probably infected late August and early October (1). It took almost two months 
before Giardia outbreak was recognized (2). The retrospective analysis carried out by 
the Bergen Legevakt (emergency health center) concluded that patients, who visited 
the emergency with diarrhea, and abdominal Giardia infection, had few characteristic, 
alarming symptoms and findings.  
During this period, approximately 2500 surplus treatments of metronidazole were 
prescribed. About 1262 subjects were diagnosed with Giardia lamblia and many of the 
infected continued to have abdominal symptoms, despite several treatments with 
metronidazole.   
These patients were thoroughly investigated without obvious cause of persistent 
symptoms.  After our best knowledge, our group (3) were first to conclude that 
eradicated Giardia infection may elicit Functional Gastrointestinal Disorders (FGID).  
Abdominal symptoms in patients referred to our outpatient clinic (82 of totally 124) 
were evaluated 12-30 months after the onset of Giardia infection and at least 6 months 
after Giardia eradication by Hanevik et al (3) and concluded that 68/82 patients 
(80.5%) had symptoms consistent with IBS and 17/82 patients (24.3 %) had functional 
dyspepsia. Abdominal problems prior to Giardia infection were not associated with 
post-infectious abdominal symptoms.   
The follow-up study of our cohort, performed by Hanevik et al (4) found persisting 
Giardia duodenal infection in about 32.3 %, with signs of duodenal inflammation, 
especially in those with illness duration less than 7 months, but these findings 
decreased over time.  Moreover, about 28 % of Giardia negative patients, had 
microscopical duodenal inflammation.  Two years after Giardia infection, these 
patients had still a high prevalence of persistent abdominal symptoms (38%) and 
fatigue (41 %) (5).   




The following risk factors have been identifying: More than one treatment course, 
treatment refractory infection, delayed education, bloating and female gender (6). 
Mesalazine® did not improve abdominal symptoms in our PI-FGID patients (7).  
In patients with persisting symptoms, Giardia infection was found to be associated 
with a high prevalence of IBS and chronic fatigue, three (8) and five years later (9), the 
perceived food intolerance (10), the long term complications with IBS, CFS (chronic 
fatigue syndrome) and reduced  quality of life (11, 12). 
Previous study showed that bacterial overgrowth is implicated in the pathogenesis 
of IBS (13). Morken et al (14) showed that the persisting symptoms after Giardia 
infection in Bergen, Norway, cannot be explained with intestinal bacterial overgrowth. 
Moreover, neither antibiotics nor bacterio-therapy had effect on symptoms in these 
patients, but they had a high fecal excretion of fat and SCFAs suggesting intestinal 
malabsorption(15). The genetic characterization of patients from our cohort showed 
that assemblage B gradually predominated over time (16).  Five years after acute 
giardiasis, the analysis of peripheral blood showed that the long term cellular immune 
response mainly occurs in CD4 T-cells (17)  with increased CD8 T-cells (18). 
 
1.2. Giardiasis  
Giardia lamblia (syn. G. intestinalis, G. duodenalis) is a protozoan parasite, infective 
to humans, with variable clinical manifestations ranging from the absence of 
symptoms to acute or chronic diarrhea (19). The WHO has estimated that more than 
280 million humans are infected every year with giardiasis and the disease was, in 
2004, included in the “neglected disease” category (20).  
As a non-invasive pathogen, Giardia attaches to the intestinal epithelium (21)mainly 
of the upper small intestine without invading tissues (22), although there is a case 
report of invasive intraepithelial giardiasis (23). The parasite can also be found in the 




stomach, ileal and colonic mucosa (24). The histological changes induced by Giardia 
are non-specific (25).  
The laboratory diagnosis of Giardia species is mainly based on demonstration of 
microscopic cyst or trophozoite in stool samples by light microscopy, but 
immunofluorescence assay (IFA), enzyme immunoassay (EIA) or polymerase chain 
reaction (PCR) methods are also used for diagnostic or research (26). Analyses of 
serum or duodenal aspirates have also been used.   
Fecal direct microscopy examination, performed to detect cysts and trophozoites, is a 
gold, standard method, economical and rapid for the diagnosis of giardiasis. Sensitivity 
of direct microscopy increases with increased number of exanimated stool sample (one 
stool sample-allow the diagnosis of 60 to 80% of infections, two stool samples 80- 
90%, three stool samples over 90%). In addition to number of examined fecal samples, 
the sensitivity of fecal microscopy is also dependent on using direct or concentration 
methods as well as trained laboratory persons (27). 
PCR is a sensitive and specific method also when there are a few cysts, but there is a 
risk of false positive results if used as a single test (28).  
There are eight Giardia genotypes, named A-H, where A and B genotypes infect 
humans and B genotype is most frequent worldwide (29). 
The pathophysiology of giardiasis is multifactorial (30, 31). The tight attachment 
between Giardia trophozoite and intestinal epithelial cells is followed by enterocyte 
apoptosis with disrupting of the epithelial tight junctions (32-34), with diffuse 
shortening of mucosal microvilli, disturbed epithelial-barrier dysfunction 
hypersecretion of Cl− and inhibition of brush-border enzymes (22, 35).  
Both innate and adaptive immune mechanisms are involved in giardiasis (29) with 
activation of mast cells, T- and B-cells, dendritic cells, immunoglobulin A and nitric 
oxide.  




In a recent novel neonatal rat model, Halliez et al (36) found that during the acute 
stage of infection, Giardia caused the translocation of commensal bacteria in rats, 
primarily paracellular with disruption of the tight junction proteins occludin and 
claudin-4. Fifty days after parasite eradication, Giardia duodenalis (assemblage A or 
B) caused visceral hypersensitivity in the jejunum and rectum that was associated with 
villous atrophy, crypt hyperplasia, increased IEL and mast cells.  
The presence of microbiota in the gastrointestinal tract, as an innate defense 
mechanism against pathogens may have an anti-Giardia effect but also protect and 
preserve gut integrity during infection.  Therefore, variability in pathology and 
susceptibility to infection could be explained by differences in microbiota composition 
between individuals (37). Extra-intestinal a long-term complications after Giardia 
infection such as ocular changes, arthritis, allergies, impaired cognitive function and 
failure to thrive have also been described (38).  
 
1.3. Functional Gastrointestinal Disorders (FGID) 
Functional gastrointestinal disorders (FGIDs) are common, unexplained 
gastrointestinal (GI) symptom complexes, without known underlying pathophysiology. 
Functional dyspepsia (FD) and the irritable bowel syndrome (IBS) are the two most 
recognized disorders. 
Functional dyspepsia (FD) is a chronic, recurrent symptom complex referred to the 
upper gastroduodenal region, characterized by postprandial fullness, early satiety or 
epigastric pain/burning (39-41).  
Irritable bowel syndrome (IBS) is a functional bowel disorder, characterized by 
recurrent abdominal pain or discomfort associated with changes in stool form and 
frequency without structural or biochemical abnormalities (42, 43). Based on 
symptoms, we can discern between the following subtypes: IBS with predominant 




constipation (IBS-C), IBS with predominant diarrhea (IBS-D) or mixed IBS (IBS-M) 
(43).   
The first symptom based criteria were made by Manning et al in 1978 (44), followed 
by ROME I (1989), ROME II (45) and ROME III criteria (42, 46). In ROME IV 
criteria are disorders classified by GI symptoms related to any combination of visceral 
hypersensitivity, motility disturbance, altered mucosal and immune function, gut 
microbiota  and CNS dysfunction (47).  
Infectious enteritis, reported for the first time in 1963 (48),  has been described as one 
of the most important risk factor for development of postinfectious dyspepsia (PI-
FD)(49) and PI-IBS (13).    
Post-infectious IBS (PI-IBS) is defined as IBS developed after an episode of acute 
infectious gastroenteritis (43),  characterized by an acute illness with ≥ 2 of the 
following clinical features; fever, vomiting, diarrhea and a positive stool culture (50).  
The site of the infection in the GI tract can determine symptom type (51). Several 
studies have shown an association between symptoms and viral (52), bacterial (53, 54) 
and parasitic (55) GI infection. The persisting post-infectious GI symptoms may last 
for months or years, as previous demonstrated in both animal (36, 56) and human 
studies (57-61).                                                                                                                                                                                                                                                                                                                                                                                                            
Salmonella gastroenteritis were found to be a significant risk factor, not only for IBS 
but also for dyspepsia and at the 1 year follow up, 1 in 7 and 1 in 10 developed 
dyspepsia or IBS, respectively (62).  
Klem et al (63) showed that the rate of PI-IBS was higher after a protozoan or parasitic 
infection (42%) rather than bacterial infection (14%), whereas overall risk of IBS was 
4-fold higher in those with infectious enteritis in the prior 12 months compared to 
controls. Grazioli et al. (64) showed that Giardia infection accounted for 6.5% of 
patients with IBS and dyspepsia. 




The longitudinal cohort analysis, performed by Nakao et al (65) using a large health 
insurance database, showed that one-year incidence of IBS was higher in persons with 
giardiasis.   
Study from our group showed that Giardia may cause chronic sequelae that can persist 
for a long time after parasite eradication such as post-infectious irritable bowel 
syndrome and chronic fatigue (3, 8, 11, 66).  The mechanisms remain unknown, but 
recent studies suggest that variability in Giardia strains, host mucosal immune 
responses, immune modulation by Giardia, the composition of host microbiota, co-
infection and host nutritional status may be important in the development of disease 
manifestations after Giardia infection (67). 
1.3.1 Epidemiology of FGID 
There is a varying prevalence of FGID depending on criteria used for classification 
and it is reported to be higher in western countries.  
The global prevalence of uninvestigated dyspepsia occurred in up to 21% (68). A 
moderate, but significant higher prevalence was found in women, smokers, NSAID 
users and Helicobacter pylori-positive individuals. It is challenging to discriminate 
between organic and functional dyspepsia since symptoms do not necessarily 
distinguish between these two forms of disease (40).  
The meta-analysis covered epidemiological population-based data across 90 studies in 
33 countries worldwide, reported the  prevalence rates of IBS between 1.1% and 45% 
(69). In the western countries, IBS affects up to 18% of adults (70). Only 8 %  of 
Norwegian adults reported  IBS symptoms with frequent somatic and psychiatric 
comorbidity, reduced health, working disability and increased use of health services 
(71).  
The prevalence of post infectious FD (PI-FD) varies between 2.8 % and 42.4%  but 
most studies on adult populations have shown the prevalence of PI-FD to be around 
10% (49) with persisting symptoms for many years (60).  




PI-IBS occurs in over 10 % of IBS patients after an episode with  GI infection, with a 
4-6 fold higher risk of developing IBS than in individuals who did not have infectious 
enteritis (63, 72-74). The risk factors are women, especially those with severe enteritis, 
as well as psychological distress and users of antibiotics during the enteritis (13, 63). 
 
1.3.2. Association between FD and IBS with other disorders  
Depending on the criteria used, the degree of overlap between IBS and FD varies 
between 15% and 42%.  Dyspeptic patients should be considered also for IBS, as there 
is an 8-fold increase of IBS in patients with dyspepsia compared with those without 
dyspepsia (75).  
In one of the longest, population-based, follow-up study of FGID subjects, Halder et al 
(76) found that patients with FD may have had IBS in the past and vice versa. IBS and 
FD patients had a high turnover in symptom status, since many episodes of symptom 
disappearance were due to subjects changing symptoms rather than total symptom 
resolution. This transition between different FGIDs suggests a common 
etiopathogenesis. 
FD and IBS may overlap with other functional syndromes as a gastroesophageal reflux 
(77), temporomandibular joint disorder, interstitial cystitis/painful bladder syndrome 
and chronic fatigue syndrome (78) as well as fibromyalgia, migraine and depression 
(79). Of GI diseases, IBS-like symptoms can occur in IBD patients in remission (80), 
coeliac disease (81) and microscopic colitis (82). 
1.3.3. Pathophysiology of FGID    
The pathophysiology of FGID is a complex and multifactorial. For several years ago, 
underlining mechanism of FGID have been based mainly on the GI motility and 
visceral hypersensitivity, but in the recent years, there had been more focus on 
infections, genetic factors, effect of diet, alteration in  the intestinal microbiota, 




immune activation, altered intestinal permeability low-grade inflammation with  
abnormalities in 5-hydroxytryptamine (5-HT) metabolism as well as disorders in 
brain- gut axis (83). 
The important risk factor in the pathophysiology of functional dyspepsia are visceral 
hypersensitivity, impaired gastric accommodation after a meal, delayed gastric 
emptying, abnormal duodenojejunal motility, acid hypersensitivity, Helicobacter 
pylori (84) and stress, particularly anxiety (85).   Sometimes, gut symptoms occur 
before anxiety, which could be can explain by brain-gut driven axis (86), but 
sometimes it is uncertain if symptoms first started in the gut or CNS (87).   
 
As FD and IBS often overlap each other, they can have common pathophysiology (51, 
88) which involves visceral hypersensitivity with GI dysmotility, increased intestinal 
permeability (89, 90), acute GI infection (13, 49), abnormalities in serotonin signaling 
and genetic predisposition (91, 92), dysregulation of the brain-gut axis (86, 93, 94) as 
well changes in the intestinal microbiome (74).  
    
1.3.3.1. Visceral hypersensitivity 
Visceral hypersensitivity, defined as increased sensitivity to distention and/or 
sensitivity to chemical food contents, is considered as a key mechanism in the pain 
perception (95) and an important contributor for symptom generation (96). The 
possible pathophysiological mechanisms have been described in details before (97, 
98). Visceral hypersensitivity is present in a subset of patients with functional 
dyspepsia (99-102) and IBS (103, 104). 
The stepwise balloon distention of different parts of the GI tract is a gold standard for 
assessing of visceral sensitivity, but this method is bothersome and non-physiological 
(105).Increased gastric visceral sensitivity to distention is associated with symptoms in 
FD patients (99)  and can be abolished by CCK-A receptor antagonist (106). One 
group (107) showed a poor correlation to abdominal symptoms. 




Between 20%-90% of IBS patients have increased visceral sensitivity (108). In 
general, IBS patients have a lower threshold for pain tolerance along the entire 
gastrointestinal tract (94). IBS patients had an increased psychological tendency to 
report pain, which in turn, is associated with psychological distress (109). In an fMRI 
study combined with barostat, IBS patients experienced markedly more pain and 
overall discomfort upon repeated distensions in the scanner, despite unaltered rectal 
sensory thresholds (110). 
 
In addition to mechanical distention or chemical stimuli, visceral sensitivity can be 
tested by either the low or high caloric nutrient drink or water (111), chemical  
stimulation, e.g. acid provocation, electrical or thermal stimulation (112). Meal 
induced symptoms are a recognized feature in FD patients. Between 60-70 % of FD 
patients showed hypersensitivity to nutrients (113, 114) with more symptoms after a 
high-fat meal than an isocaloric high carbohydrate meal (115). Mucosal afferents in 
the stomach sense the presence of the luminal contents via mechanical and chemical 
receptors. Ingested food is exposed to vagal afferents causing distention of the 
stomach wall which activates mechanoreceptors. There are two types of 
mechanosensitive vagal afferents ending in the stomach, mucosal receptors and 
tensions receptors. Tension receptors send signals to the CNS about the level of 
stomach distention, which is important for regulating food intake, generating the 
sensation of satiety and fullness as well control of gastric emptying. Both chemo- and 
mechanosensitive receptors have an important role in the generation of satiety 
sensations, nausea and vomiting via chemical and osmotic stimuli.  
A study using gastric barostat combined with a liquid meal showed that FD patients 
had a significantly greater postprandial sensitivity to balloon distention compared to 
fasting sensitivity. Only postprandial sensitivity was correlated to the severity of 
symptoms of meal-related FD (116). FD patients may also have abnormal central 
processing of visceral perception (117). 




In the animal model of post-infective bowel dysfunction with Trichinella spiralis, 
transient infection lead to persistent gut dysfunction with increased sensitivity(118). In 
the new rat model of post-giardiasis IBS, Halliez et al (36) showed that rats expressed 
visceral hypersensitivity to luminal balloon distension in the jejunum and rectum, 50 
days after infection with Giardia duodenalis (assemblage A or B), long after the 
parasite was cleared. 
           
1.3.3.2 Gastric accommodation  
Gastric accommodation is one of the most important pathophysiological mechanisms 
in FD (119).   
It consists of receptive- and adaptive relaxation, an intrinsic vagovagal reflex that 
dilates the proximal part of the stomach in response to a meal without following an 
increase in pressure (120).  About 40 % of FD patients have impaired proximal gastric 
accommodation (121) with altered meal distribution and impaired relaxation of the 
proximal stomach.   
The barostat has been considered as a gold standard for measuring gastric 
accommodation, but the procedure is invasive, time-consuming and uncomfortable. 
Other methods for assessing accommodation (122) are imaging with magnetic 
resonance (MRI) (123), single photon emission computed tomography (SPECT) (124) 
or ultrasonography (US) (120, 125, 126).  
The intragastric volume and thus indirect relaxation of the stomach can be evaluated 
by measuring the size of the stomach with ultrasound. Gilja et al (127) were first to 
develop a ultrasonographic methods to assess gastric accommodation. 
As a non-invasive test, drink tests with water or nutrients are used to assess the 
sensation of fullness and early satiety after meal ingestion. A drink test may be used as 
a surrogate marker of proximal stomach function, predicting impaired gastric 




accommodation (128, 129). These methods showed that 40-60 % of FD patients had 
impaired accommodation to a meal (130, 131).  
The impaired relaxation of the proximal stomach, reported in a high proportion of FD 
patients, can be restored by the 5-hydroxytryptamine (5-HT1) receptor agonist 
sumatriptan, which induces a relaxation of the proximal stomach in humans (121, 
132).  Patients with presumed PI-FD had more prevalent impaired accommodation 
compared with unspecified-onset dyspepsia. 5-HT1 agonist sumatriptan relaxed the 
stomach in controls and patients with unspecified-onset dyspepsia but not in patients 
with presumed post-infectious dyspepsia, whereas the NO donor amyl nitrite relaxed 
the stomach in all subjects (133). 
 
1.3.3.3 Gastric emptying (GE)  
After a meal, ingested nutrients enter the stomach and the intestine, inducing the 
relaxation of the proximal stomach (enteral-gastric reflex). This reflex is vagus 
mediated and depends on the type and amount of nutrients. Infusion of duodenal 
nutrients increases gastric sensitivity to distention (113).Transport of nutrients to the 
duodenum depends on gastric emptying.  
Delayed gastric emptying for either solids or liquids, occurs in a subset of FD patients, 
ranging from 25 % to 50 % (134). Scintigraphy, a non-invasive test of gastric 
emptying, is considered to be the gold standard, but it is an expensive, time-consuming 
and not widely available procedure.  
Ultrasonography (US) is an inexpensive and widely distributed real-time technique, 
without radiation, that can be applied repeatedly and at the bedside (135). Since 
gravity affects the propulsion of gastric content, accommodation should be measured 
in a sitting or standing position (120).  In combination with a low caloric meal, US has 
been used to study gastric motility (136), accommodation (127, 137) and gastric 
emptying (138) in FD patients.  




In FD patients, by using breath test, delayed GE of solids was associated with 
postprandial fullness and vomiting, whilst delayed GE for liquids was related to 
postprandial fullness and early satiety (134).  
Delayed gastric emptying has also been reported in a subset of IBS patients. IBS 
patients with overlapping dyspepsia had significantly delayed gastric emptying, tested 
by scintigraphy, that was associated with postprandial fullness and nausea, while IBS 
patients without overlapping dyspepsia had normal gastric emptying of solids (139).  
The CCK-A antagonist, Loxiglumide, has a prokinetic effect and is effective in the 
treatment of FD symptoms (140). The CCK-1 receptor antagonist dexloxiglumide, 
accelerates gastric emptying and delays proximal but not overall colonic transit in 
patients with C-IBS (141).  
 
 
Fig. 1 Assessment of the accommodation of the proximal stomach by using 2 D (A) 
and 3D (B) ultrasound.    
 
1.3.3.4 Low-grade inflammation 
The recent studies emphasized the importance of low-grade inflammation in both FD 
(101), (49, 142), IBS (143) and PI-FGID (13, 92). 




Altered mucosal immune cells, including impaired number of EC cells (144) with 
alterations in 5-HT and increased IEL and T lymphocytes (50, 145, 146), changes in 
the peripheral blood  T cells (147, 148), increased mast cell activation (149-151), 
eosinophils (150, 152) as well as food intolerance and gut-microbial interactions (92) 
have been implicated in the disease process.  
Increased number of colonic EC  cell counts in IBS patients correlate with visceral 
hypersensitivity (153). Increased 5-HT release, assessed with quantitative 
immunohistochemistry on colonic biopsies, in IBS patients correlates with mast cell 
counts and the severity of abdominal pain, suggesting that 5-HT contributes to the 
development of abdominal pain (154).  PI-IBS patients, after Campylobacter jejuni 
enteritis, have persistent low-grade inflammation within rectal mucosa, with an 
increased number of lamina propria T lymphocytes and enterochromaffin (EC) cells, 
serotonin bioavailability as well as increased small intestinal permeability (53). 
Several studies reported evidence of low-grade inflammation which may persist up to 
4 years (53, 58).  
 
1.4. Gut endocrine cells                 
Neuroendocrine system of GI tract consists of the endocrine cells and the enteric 
nervous system (ENS). Enteroendocrine cells (EEC), as one of the largest endocrine 
organ in the body representing 1 % of the intestinal epithelium, are dispersed among 
the epithelial cells in the gut mucosa except for esophagus (155). From the base of 
intestinal crypts, EEC cells differentiate from stem cells and migrate up the crypt-
villus axis. They had a key role in the regulation of food intake, GI secretions, and 
motility (156) releasing their secretory product by exocytosis at the basolateral 
membrane upon mechanical, chemical or neural stimulation. They are called “the gut 
sensors” as they have specialized microvilli that project into the gut lumen, sensing 
luminal nutrients and then secreting more than 20 peptides, including cholecystokinin 




(CCK), glucagon-like peptide 1 and 2 (GLP-1, GLP-2), glucose-dependent 
insulinotropic peptide (GIP), peptide YY (PYY), somatostatin and ghrelin, as well as 
bioactive amines such as serotonin (5-HT). The release of CCK is triggered by protein 
and fat. 
There is an inetraction between  neuroendocrine and immune systems in addition  to 
gut microbiota. The alterations in the number of EEC during infection have been 
reported in both animal (56, 157, 158) and human studies (58, 159).   
 
1.4.1. 5-HT (5-hydroxytryptamine)      
Serotonin (5-hydroxytryptamine, 5-HT) is an important enteric mucosal signaling 
molecule, produced by enterochromaffin (EC cells). The serotonin secreting cells are 
found throughout the GI tract.  Approximately 95 % of the 5-HT is synthesized from 
EC cells (160) as well as in serotonergic neurons of the ENS (161).  
5-HT is synthesized from amino acid tryptophan (5-HTP) by the rate limiting enzyme 
tryptophan hydroxylase (TPH). There are 2 types of TPH, TPH1 (predominantly found 
in EC cells) and TPH2 (in all serotonergic neurons)(162) . Serotonin is inactivated by 
the serotonin reuptake transporter (SERT). 5-HT has been implicated in a number of 
GI diseases (163). It plays a major role in promoting of intestinal motility through a 
combination of neuronal and mucosal mechanisms. Serotonin (5-HT) has also an 
important role in visceral hypersensitivity (164). 
 
1.4.1.1. 5-HT3 antagonist             
There are 7 major groups of 5-HT receptors which have an important role in the 
regulation of inflammatory and immune responses (165). It is expressed in the 
numerous cells of GI tract, as EC cells, Goblet cells and interstitial cells of Cajal (ICC) 




(166).  After ingestion of meal, EC cells secrete serotonin into the gut wall and 
stimulate primary afferent neurons, which start the peristaltic reflex (160).  
In animal study, intestinal perfusion with carbohydrates inhibits gastric emptying via 
vagal and spinal capsaicin-sensitive afferent pathways and pretreatment with an 5-HT3 
antagonist can abolish carbohydrate induced inhibition of gastric emptying (167).  
5-HT3 receptors are involved in acid-induced duodenogastric sensitization in healthy 
volunteers (168), where 5-HT3 receptor antagonist ondansetron decreased gastric 
sensitivity during duodenal acid infusion and gastric distension and improve nausea 
and vomiting (169). 
In IBS-D patients (170), 5-HT3 receptor antagonist ondansetron induced 
rectal relaxation with increased rectal compliance but did not alter gastric compliance 
or visceral perception.  5-HT3 receptor antagonist alosetron (171) modulated 
abdominal pain and discomfort in IBS patients. 
 
1.4.2 Cholecystokinin (CCK)                           
Cholecystokinin (CCK) is a brain-gut peptide released from the I cells of the 
duodenum and jejunum in response to luminal nutrients, especially lipids and proteins, 
inducing satiety via vagal afferents (172). CCK has an important role in the ingestion, 
absorption and digestion of food.  It inhibits gastric motility and emptying of the 
proximal stomach and pylorus via a capsaicin-sensitive vagal pathway (173). 
A high fat meal provokes more symptoms in FD patients, with a greater concentration 
of fasting and postprandial plasma CCK compared to healthy subjects (115). One 
study showed that IBS patients have increased levels of CCK in plasma and rectal 
mucosa (174). El-Salhy et al (175) found that IBS-D  had significantly reduced the 
density of duodenal CCK-immunoreactive cells. 




In acute giardiasis in humans, plasma CCK levels were found to be elevated (159). An 
animal model with Giardia infection showed increase CCK levels, which trigger mast 
cell degranulation and contractions of longitudinal smooth muscle (176).   
CCK-A and 5-HT3 receptors mediate the nutrient-induced reduction of food intake 
and gastric emptying (167). 5-HT3 receptors mediate CCK induced satiation through 
indirect mechanisms involving gastric emptying and gastric distention. 
 
1.5 T- and B- lymphocytes       
The immune system consists of innate and adaptive immunity and the mucosal 
immune system provides a first defense line of the inner body surface (177). More 
than 80 % of the body`s activated B-cells are terminally differentiated to plasmablasts 
and plasma cells (178, 179).  The mucosa of the gut can be divided into the inductive 
site and effector site (180). The inductive site consists of gut-associated lymphoid 
tissue (GALT) and Peyer's patches (with B-cell follicles and M cell -containing 
follicle-associated epithelium). The effector site consists of lamina propria (with B- 
cells, Ig-producing plasma cells, and T- cells) and epithelium (mainly T-cells) (177). 
Intraepithelial lymphocytes (IELs) are located in direct contact with the enterocytes, in 
the close relation to the antigens in the gut lumen and thus form the first defense 
against pathogens (181).  Intraepithelial lymphocytes (IELs) belong to the T- cell 
population and are interspersed between epithelial cells of both the small and large 
intestine (182). 
The upper limit of IEL number in the proximal small intestine is around 25 IELs/100 
epithelial cells (183, 184).  The majority of IEL in the human intestine are CD8+ with 
a few CD4+ cells, especially in the small intestine (180). T- cells in lamina propria are 
scattered throughout the lamina propria of the small bowel and colon and consist 
mainly of CD4+cells.  




CD4+ T cells have an important role in immune protection. They help B-cells to make 
antibodies and they recruit neutrophils, eosinophils, and basophils to the site of 
infection by secretion of various cytokines and chemokines.  
The mucosal immune response against Giardia starts with an early response, with 
intestinal barrier function, secretion of pro-inflammatory molecules such as IL-6 
derived from dendritic cells and mast cells, and CD4+ and CD8+ T cells. The late 
response starts with activation of CD4+ T memory cell and B- cells.    
It has also been shown that people who were infected by Giardia in the Bergen 2004 
outbreak still had elevated Giardia specific CD4 T cell responses 5 years later (17). 
B-cells and plasma cells are effector cells of humoral immunity and a part of the 
adaptive immune system. Through antigen presentation, cytokine secretion and 
antibody production, they have an important role in the initiation and the termination 
of immune responses. B-cells  play important role in protection against Giardia 
infection. The animal study showed that B-cell deficient mice failed to produce 
antibodies against Giardia and developed chronic infection (185).  
In the waterborne outbreak of giardiasis in Vermont (186) serology taken in the 
convalescent phase showed higher levels of parasite-specific antibody IgG and IgA but 
not IgM. During a second outbreak of giardiasis in the same area (187), previously 
infected cases were less likely to be re-infected suggesting an acquired, protective 
immunity lasting at least 5 years. 
 
Accordingly, we hypothesized the following: 
1. PI-FGID patients may have increased visceral sensitivity in upper GI tract.  
2. 5-HT and EC cells may be increased in plasma and duodenum. In addition, we 
assess the role of CCK. 




3. To study alterations in duodenal intraepithelial (IEL) and in lamina propria 
(Lpv/Lpc) T  cells (CD3+, CD4+ and CD8+) and B (CD20+) cells.  
2.  AIMS OF THE STUDY 
The aim of this dissertation was to study visceral sensitivity and low-grade duodenal 
mucosal inflammation, assessed by EC cells, serotonin (5-HT) and cholecystokinin 
(CCK) in patients with functional gastrointestinal disorders after cleared Giardia 
infection.  To our knowledge, this has not been described before.   
The specific aims in this study were:   
Paper I 
-to investigate visceral hypersensitivity of the upper GI tract in patients with post 
infectious Giardia-induced abdominal symptoms using a low-caloric soup meal 
combined with non- invasive 3D ultrasonography and to assess the effect of the 5-HT3 
antagonist ondansetron in these patients. 
Paper II 
-to determine the importance of duodenal serotonin (5-HT) and CCK containing EC 
cells as well as plasma 5-HT and CCK in patients with prolonged abdominal 
symptoms after successful treatment of Giardia infection. We hypothesized that 
altered 5-HT and CCK signaling could be associated with the development of Giardia-
induced PI-FGID. 
Paper III 
- to describe quantitatively morphological changes in duodenal mucosal T- and B-
lymphocytes in patients with persisting abdominal symptoms (PI-FGID) (average 11 
months) after resolution of Giardia infection and compare these with chronic 
giardiasis patients, post-giardiasis recovered controls and healthy controls.  





3. MATERIALS AND METHODS  
3.1 Study population 
 
Fig 2. Giardia cohort populations included in all three papers of this thesis. 
Patients were referred to our out-patient clinic due to persisting abdominal symptoms 
after Giardia outbreak in Bergen in 2004. In these patients, Giardia had been 
successfully eradicated, confirmed by at least three negative microscopy samples and 
later verified with negative PCR. Our cohort patients went through structured 
interview 12–30 months after the onset of Giardia infection, and at least 6 months 
after Giardia eradication, as described in detail previously by Hanevik et al (4). 
Due to persistent symptoms, gastroduodenoscopy with duodenal biopsies were 
available from 28 patients with chronic giardiasis (CG) patients and 72 PI-FGID 
patients (66 of these were randomly selected for this study). Chronic giardiasis patients 
were including in Paper III for comparison of histological changes with other groups. 




As a control group in Paper I and II, we used 19 previously young, healthy subjects, 
who had Giardia infection at the same time as PI-FGID patients, with laboratory-
confirmed giardiasis during the outbreak and recovered rapidly after treatment with 
metronidazole. The recovered controls were recruited by phone from primary care, 
examined 12-19 months after onset of the gastroenteritis, and were asymptomatic at 
the time of inclusion.  
In Paper III, we recruited by advertisements, 16 healthy, previous non-Giardia 
exposed controls, without persisting GI or other symptoms. They went through the 
same investigations as the cases and served as healthy controls (HC).  
3.2. Diagnostic criteria and symptom scores 
From the start of the outbreak, all subjects fulfilled abdominal symptom score, 
determined by an irritable bowel syndrome symptom questionnaire (188), including 
nausea, bloating, abdominal pain, diarrhea, constipation. These symptoms were 
assessed using an ordinal scale from 0 – 10, with 0 = no symptoms and 10 = severe 
symptoms. 
In addition, shortly after the start of Giardia outbreak, we used a validated Norwegian 
version of the ROME II questionnaires for IBS (189) and FD (39). 
In Paper II, abdominal symptoms (abdominal pain/discomfort, nausea, fullness and 
bloating) were assessed before (time) 30 min and every 30 min after a carbohydrate 
rich meal test, up to 4 h postprandially, by using the ROME II dyspepsia questionnaire 
(39).The severity of symptoms was scored using the scale 0 = none; 1 = mild; 2 = 
moderate; 3 = severe. The overall postprandial dyspepsia score was calculated by 
adding the total for each of the four symptoms over the 4-h postprandial period (0–96). 
In Paper II, PI-FGID patients and recovered controls completed the Hospital Anxiety 
and Depression Scale (HAD) (190), Eysenck Personality Questionnaire, Short 12-item 
scales (EPQ-N) (191) and Short Form Nepean  Dyspepsia Index (SF-NDI) (192). 






3.3.1. Gastroduodenoscopy with duodenal biopsy specimens 
Following an overnight fast, gastroduodenoscopy was performed in patients, recovered 
controls and healthy controls. A total of six biopsy specimens were taken from the 
distal part of the duodenum. Three biopsy specimens were placed in 4% buffered 
formalin for routine histological analysis and delivered to the Department of Pathology 
at the same day. Three biopsies were snap frozen in liquid nitrogen and then stored at -
80°C, later analyzed for 5-HT and 5-HIAA content.  
Repeated duodenal biopsies were available in 11 PI-FGID patients, examined first 3-7 
months after onset of symptoms (when eight were still Giardia positive and three were 
Giardia negative) and then 16-19 months after onset of symptoms (when all 11 were 
Giardia negative).  
3.3.2. Diagnostic methods of Giardia spp. 
In the beginning of the Giardia outbreak, conventional microscopy following standard 
formalin-ether concentration was used, but this procedure is time-consuming and 
requires experienced personnel (193). Therefore, the ImmunoCard STAT! 
Cryptosporidium ⁄ Giardia rapid assay (Meridian Bioscience, Inc., Cincinnati, OH, 
USA) faecal antigen test were used, which has been reported to have high sensitivity 
(81–93.5%) and specificity (>99%) (194, 195). However, in this thesis, diagnostic of 
giardiasis has not been the aim of the study, therefore it is not described in detail here.    
3.3.3. Ultrasonography  
In Paper I, three-dimensional ultrasound imaging was performed with a Logic 9 
scanner (GE Medical Systems, Milwaukee, WI, USA) with a 3,5 MHz transducer 
interfaced to a magnetic position and orientation measurement system. The Bird 
system (Ascension Technology Corp., Burlington, VT, USA) was calibrated before 




each 3D acquisition that was performed at maximal satiety. The recording was stored 
on a PC workstation for later analysis using dedicated software (Echopac3D, Horten, 
Norway). This acquisition procedure and software have demonstrated very good 
accuracy in volume estimation (125, 137, 196). All examinations were performed by 
the experienced doctor to avoid differences in interobserver variation. All gastric 
volume measurements were performed blinded after study completion. Gastric 
emptying (GE %), measured once - after a meal, was defined as the fraction of the 
meal emptied from the stomach immediately after a meal [(drinking capacity) 
intragastric volume)/drinking capacity · 100%)].  
 
3.3.4. Drink test (low-caloric soup meal) 
In Paper I, we used the low-caloric soup meal (Toro® clear meat soup; Rieber & Søn 
A/S, Bergen, Norway) in combination with 3D ultrasound. The subjects ingested low 
caloric soup meal; 100 mL every minute, until maximal drinking capacity and the 
volume of the stomach was then assessed using 3D ultrasound. The soup was first 
boiled and then cooled to 37° C. It contained 1.8 g protein, 0.9 g fat, 1.1 g 
carbohydrate and non-soluble seasoning (0.2 g) per 500 mL (4 kcal 100 mL)1). The 
pH of the soup varied between 5.4 and 5.7, and the osmolarity was350 mOsm kg)-1 
H2O.  
    





Fig. 3 Three-dimensional ultrasound (3D US) in combination with the low caloric 
soup meal.  
 
3.3.5 A double-blind, randomized, placebo-controlled study with 5-HT3 
antagonist Ondansetron® 
Patients receiving 5-HT3 antagonist Ondansetron® were studied on two separate 
occasions, with 7-14 days interval between examinations. They received oral treatment 
with either Ondansetron®, 8 mg or placebo, 20 p.m. the day before and the next day 1 
h 30 min before the drink test. Placebo and study medication (Zofran, Glaxo Smith 
Kline) were identical in appearance. Study subjects and the clinical investigators were 
blinded to the treatment assignment until the data analysis was completed. 
 
3.3.6. Carbohydrate-rich test meal 
In Paper II, we used a similar carbohydrate-rich meal as described previously (197), 
which consists of 100 g boiled pasta in 100 mL tomato soup (Toro, Rieber& Søn, A⁄ S 
Bergen, Norway), 50 g white bread (two slices), 8 g soft margarine, one wheat bun,10 




g jam (500 g sugar ⁄ kg) and 300 mL tap-water (calorie content of 557 kcal-
carbohydrates, 63%, fat, 27%, protein,10%). 
 3.3.7 Extraction of 5-HT from biopsy sample and analysis of 5-HT and 5-HIAA 
by HPLC and blood samples for serotonin (5-HT) and cholecystokinin analysis   
These analysis were performed by Spiller RC et al. and are described in detail in Paper 
II (198). 
3.3.8. Immunohistochemistry 
Endocrine cells distribution in humans was previously examined by 
immunohistochemistry (199). 
In Paper II, the standard technique was used to prepare each biopsy for 
immunohistochemistry for serotonin-producing enterochromaffin (EC) cells, as 
described previously (200), 5-HT(56), CCK producing enteroendocrine cells (201), 
mast cells and the nonspecific marker for all enteroendocrine cells, Chromogranin A 
(CgA). 
In Paper III, we performed immunohistochemistry of T- and B-lymphocytes. 
Formalin-fixed paraffin-embedded duodenal specimens were cut into 4 µm sections, 
de-paraffinized in xylene and rehydrated through graded ethanol series and distilled 
water. 
After heat-induced epitope retrieval (HIER) in Tris-EDTA buffer, pH 9.0 for 15 
minutes at 350W, endogen peroxidase activity was blocked with 0.3% peroxide 
(Dako) for 5 minutes. Tissue was then incubated with primary antibodies: CD3 
(Polyclonal Rabbit Anti-Human CD3), CD4 (Monoclonal Antibody NCL-CD4-IF6, 
clone IF6), CD8 (Monoclonal Mouse Anti-Human CD8α, clone C8/144B) and CD20 
(Monoclonal Mouse Anti-Human CD20, clone L26). EnVision (DAKO 5007) was 
used as a secondary antibody for 30 minutes, with DAB as chromogen. Sections were 
counterstained with Haematoxylin (Dako S3301). 





3.3.9. Computerized image analysis 
In Paper II, 5-HT cells and mucosal mast cells were counted using the Weibel 2 
graticule method as previously described (56, 202) and results expressed as cells per 
mm2.  
Quantifications method for CCK cells in Paper II has been described elsewhere (203). 
Morphometric analysis for CCK immunoreactive cells was performed using the 
Olympus program ‘Cell P’, with an x 40 objective and in a frame representing an area 
of 0.13 mm2 of the tissue. The number of nucleated CCK cells in the crypts was 
counted in coded slides from 20 randomly chosen fields from three different sections 
from each individual. All measurements were performed by the same person and 
double-checked by an experienced person. 
In Paper III, quantification of duodenal T- and B-lymphocytes has been described in 
detail.  
The numbers of intraepithelial lymphocytes (IEL), located above the basal membrane, 
per 100 epithelial cells were counted on five, well-orientated villi with longitudinal 
sections and expressed as the number of IELs per 100 epithelial cells (204). Lamina 
propria villous (Lpv) lymphocytes located underneath epithelial basal membrane, 
assessed in five villi and then expressed as average cell counts per area (cell 
count/mm²). Lamina propria crypt lymphocytes (Lpc) were counted per area within 
five consecutive, non-overlapping 200x-fields of crypt lamina propria and the results 
averaged (cell count/mm²). Positive cells in the vicinity of lymphoid follicles or 
clusters were not taken into consideration. Only cells with a visible nucleus were 
considered as positive and counted. 





Fig. 4 Duodenal IEL, Lamina propria villus (Lpv) and Lamina propria crypt (Lpc) 
cells in PI-FGID 
 
3.4 Ethics 
All studies were approved by the Regional Committee for Medical Research Ethics 
and conducted according to the Declaration of Helsinki. All data collection and 
protection were approved by the Norwegian Social Science Data Services.  
 
3.5 Statistical analysis 
Differences between groups were measured using the parametric (paired- and unpaired 
Students t-test) or non-parametric (the Wilcoxon’s or Mann-Whitney test) test. The 
area under the postprandial concentration curve for used for CCK plasma 
concentrations. The relationship between symptoms score and CCK or 5-HIAA was 
calculated using regression analysis (Paper II). Correlations were assessed using 
Pearson (parametric data) or Spearman rank test (non-parametric data). Kruskal Wallis 




was used in Paper III for assessing of differences between groups for age, illness 
duration, and CD cell counts. Chi-square (Fisher exact) test was used in Paper III for 
categorical values. The Wilcoxon paired test was used in paper II to compare 
lymphocytes in repeated biopsies.  
Data were analyzed using Graph Pad Prism 4 (San Diego California, USA) and SPSS 
14.0 (Chicago, Illinois) for Windows.       
 
4. BRIEF SUMMARY OF RESULTS 
PAPER I 
Increased visceral sensitivity in Giardia induced post-infectious irritable bowel 
syndrome and functional dyspepsia. Effect of the 5-HT3 antagonist ondansetron. 
Twenty-two patients with IBS and FD after Giardia infection showed increased 
visceral hypersensitivity with lower drinking capacity and reduced gastric emptying 
compared to 19 recovered controls. They had more symptoms both fasting and 
postprandially than recovered controls. The subset of IBS/FD patients (n=15) 
underwent double-blind, randomized, placebo-controlled study with the 5-HT3 
antagonist ondansetron, that had no effect on symptoms except of less nausea 
postprandially.  For the interpretation of results, we refer to Discussion chapter. 
PAPER II 
The relative importance of abnormalities of CCK and 5-HT (serotonin) in 
Giardia-induced post-infectious irritable bowel syndrome and functional 
dyspepsia. 
PI-FGID patients (n=32) had increased numbers of CCK cells and lower numbers of 
EC cells, compared to recovered controls (n=19). After consuming of the high-
carbohydrate meal, the subgroup of PI-FGID patients (n=21) had significantly lower 




plasma 5-HIAA, before and after a meal, as well as more dyspepsia compared with 




Prolonged duodenal mucosal lymphocyte alterations in patients with and without 
post-infectious functional gastrointestinal disorders after Giardia infection. 
Duodenal mucosal intraepithelial lymphocytes (IELs) and lamina propria CD3, CD4, 
CD8, and CD20 lymphocytes were quantified in 28 chronic giardiasis (CG) patients, 
66 PI-FGID, 19 recovered controls (RC) and 16 healthy volunteers (HC). There was 
assessed the associations with illness duration, abdominal symptoms, and histology 
grade. Duodenal CD4 IEL were significantly elevated in CG, and then decreased, 
followed by an upward trend after one year in both the PI-FGID and RC groups. 
Duodenal lamina propria crypt CD4 T cells were decreased in CG and stayed low for 
about 14 months before normalizing in both PI-FGID and RC group. Lamina propria 
CD20 cells were persistently elevated in all three Giardia exposed groups. Biopsies 
with microscopic inflammation showed increased lamina propria CD20 levels. 
 
5. DISCUSSION 
Due to persistent symptoms, our cohort patients were thorough an extensive follow up 
(3, 4, 8, 11). We found no organic cause that could explain the long-term symptoms 
and concluded that patients had symptoms consistent with Giardia induced Post-
Infectious Functional Gastrointestinal Disorders (PI-FGIDs). 
In this thesis, we found that patients with persisting abdominal symptoms, after 
eradicated Giardia,  most of them with overlapping FD and IBS, had increased 




visceral sensitivity with delayed gastric emptying, as assessed by ultrasound (US), in 
combination with a low-caloric soup meal. 5-HT 3 antagonist had effect on the 
postprandial nausea only (Paper I). 
In Paper II, after intake of carbohydrate-rich meal, PI-FD/IBS patients had lower 
plasma serotonin (5-HT), assessed as 5-HIAA, with more dyspepsia symptoms, lower 
number of duodenal 5-HT containing EC cells and increased number of duodenal CCK 
cells compared to recovered controls. 
In Paper III, all three Giardia exposed groups had decreased duodenal lamina propria 
crypt (Lpc) CD4 cells, that normalized approximately 14 months after the acute 
illness, while elevated dduodenal Lpc CD20 cells appeared to last longer than 19 
months in all three Giardia exposed groups.  
 
Visceral sensitivity  
In general, FGID patients often experience worsening of symptoms after meal intake 
with subsequent increased visceral sensitivity (205). Increased visceral sensitivity has 
been shown to correlate with symptoms in a subset of FD patients (99, 102) and 
impaired accommodation in the acute onset of FD (133). IBS patients also expressed 
visceral hypersensitivity with the higher scores for all symptoms, except for nausea, 
both fasting and after intake of meal with 540 kcal (36% fat, 15% proteins, 49% 
carbohydrates; 8.9 g fiber) (206). 
In Paper I, we hypotesised that increased gastric sensitivity could be important for 
symptom generation in PI-FGID patients after cured Giardia infection. We used the 
low-caloric meat soup test combined with  ultrasound, as an non-invasive, 
inexpensive, and effective method to assess visceral sensitivity and  gastric emptying 
(120).  




Clinical overlap of FD and IBS is very common (207). Of all PI-FGID patients 
included in the Paper I, approximately over 2/3 had overlapping FD and IBS.  
In fasting state, PI-FGID Giardia patients had significantly higher scores of abdominal 
pain, discomfort, nausea, and fullness compared to recovered controls. Postprandially, 
they expressed significantly more pain, discomfort as well as pooled symptom score 
than recovered controls.  
After subgroup analysis, we found that patients with overlapping FD/IBS (n=15) had 
more fullness in fasting state compared to only IBS (n=7), otherwise there was no 
difference in symptoms between these two subgroups. Similar findings, with more 
epigastric pain, nausea, and upper GI discomfort both before and after the soup meal in 
both FD and IBS patients were reported by Steinsvik et al (208). Bisschops et al (114) 
reported that postprandial fullness in FD patients, is the most severe symptom 
aggravated by a meal and aproximately 50% of subjects with dyspeptic complaints in 
the general population, have postprandial symptoms that are often correlated to fasting 
symptoms. Other reported that FD patients with coexisting IBS had a greater overall 
symptom severity with hypersensitivity to distention tested by gastric barostat (209) 
and only postprandial, not fasting, gastric distention thresholds are related to the 
severity of meal-related symptoms (116) . 
Our PI-FD/IBS patients showed delayed gastric emptying for low-caloric soup as 
measured by 3D US. Other studies show different findings, depending on the methods 
used. By using scintigraphy, Stanghellini et al (139) found that IBS patients with 
overlapping FD had significant slower emptying of solids compared to IBS without 
dyspepsia. Kindt et al (144) showed that PI-FD patients had delayed gastric emptying 
for solids, without an observable difference for liquids when tested by breath test for 
liquids and solids. Sarnelli et al (134) showed that delayed gastric emptying of solids 
or liquids in a subset of FD patients was associated with postprandial fullness and 
early satiety.  




In Paper I, we did not measure gastric specific accommodation, but overall volume 
gives an indirect measure about it.  
We found that fullness and satiety were positively correlated to the total gastric 
volume at maximal satiety in the PI-FGID patient group. It could be possible that 
distention of the stomach and subsequent stretch of mechanoreceptors may explain the 
symptoms.       
 
Effect of 5-HT3 (Ondansetron®) 
Previous study (210) showed improvement of nausea after treatment with a 5-HT3 
antagonist without  changing of gastric motility. Moreover, the ingested meal at 
maximum satiation was significantly increased by ondansetron (211). 
Therefore, we hypothesized that 5-HT3 antagonist can improve symptoms in our PI-
FGID patients. In a subgroup of PI-FGID patients (Paper I), with overlapping FD and 
IBS, the effect of 5-HT3 antagonist (Ondansetron®) on symptoms was tested by using 
ultrasound combined with the low caloric soup meal in addition to symptom 
questionnaires. They received  oral treatment  with either ondansetron , 8 mg or 
placebo, 20 p.m.  the day before and  the next day  1 h and 30 min before the  drink 
test. 5-HT3 antagonist resulted with had less postprandial nausea in the treatment 
group compared to placebo. Otherwise, there was no effect on other symptoms, 
drinking capacity, 3D volumes, or gastric emptying.  
The possible lack of effect on other symptoms could be explained by the small patient 
size or a low dose of 5-HT3 antagonist.  
Previous studies showed that 5-HT3 antagonist (Alosetron®) relieved symptoms in FD 
(212) and upper GI symptoms in IBS patients (213).  Similar findings were shown in 
healthy subjects by Kuo et al (214) using SPECT with assessing fasting or 
postprandial gastric volumes after a liquid meal (nutrient drink). They found that 5 




HT-3 antagonist reduce nausea and bloating, but not pain or fullness, without increase 
in gastric maximal tolerable volumes, suggesting a role for 5-HT3 in a visceral afferent 
function. 
We found also that nausea was negative correlated to maximal drinking volumes, 
indicating that it inhibits maximal drinking capacity. Postprandial symptoms after low-
caloric meal soup in our PI-FD/ IBS patients may arise from mechanical stimulation of 
afferent nerves. 
Feinle et al (169) found out that the gastric relaxation is not always necessary for 
reduction of postprandial symptoms, since they observed a reduction in symptom 
scores without a significant increase in the postprandial relaxation of the stomach, so 
the effect may be well be related to drug effect on chemo-sensitive afferents. 
Another explanation with possible activation of duodenal chemoreceptors in our 
cohort patients may be of less importance since our PI-FGID patients had decreased 
gastric emptying.  
Anyway,  an interaction between mechanical and chemical stimuli in the upper 
gastrointestinal tract is important in the induction of postprandial sensations and 
symptoms in humans(215). 
 
Plasma serotonin and cholecystokinin in post-Giardia FGID 
After our best knowledge, there is no human study on duodenal 5-HT and CCK in 
patient with persisting symptoms after cured Giardia infection.  
Therefore, the aim of Paper II was study plasma and duodenal 5-HT and CCK levels in 
PI-FGID patients. We chose to use carbohydrate rich meal, as it is previously showed 
that 5-HT levels increased after carbohydrate meal, compared to fat and protein rich 
meal (216). The meal ingestion is often associated with gastrointestinal symptoms in 




FGID patients (99, 114, 116, 134). 5-HT has important role in postprandial symptoms, 
in both healthy (217), FD (218)  and IBS patients (219). Cholecystokinin (CCK) 
release, from enteroendocrine cell, is stimulated by luminal releasing factors, secreted 
after meal ingestion. IBS patients have increased fasting and postprandial plasma 
levels of CCK (220).  
Analysis of plasma 5-HT and CCK as well duodenal mucosal 5- HT in Paper II, were 
performed in England by Spiller RC and co, who has a long experience with serotonin 
and PI-IBS(197, 221).  
The fasting 5-HT levels (Paper II), in plasma rich platelet, did not different between 
PI-FGID and recovered controls. After a carbohydrate meal challenge, PI-FD/IBS 
patients had a significantly lower plasma 5-HIAA, at all time points up to four hours 
after a carbohydrate reach meal, compared with recovered controls.  
This is in a line with study done by Cheung 2013 (218), where FD patients had 
decreased basal ad postprandial  plasma levels of 5-HT after intake of carbohydrate 
rich meal.  Dunlop et al (221) found lower platelet poor plasma 5-HT, from 0 to 180 
min after carbohydrate rich meal, in IBS-C patients, compared with PI-IBS and 
healthy controls. PI-IBS patients showed significantly higher peak of postprandial 
plasma 5-HT. Atkinsons al (222) reported lower concentrations of plasma 5-HT, 
following meal ingestion in only IBS-C, not IBS-D patients. Other group (197) found 
that IBS-D, after a standard carbohydrate meal (457 kcal), had a significant higher 
postprandial plasma 5-HT compared to healthy subjects.  
We found no correlation between symptom scores and 5-HIAA, neither fasting nor 
postprandially. 
In addition to 5-HT (Paper II), we assessed plasma CCK before and after carbohydrate 
rich meal, without finding significant differences between the patients and recovered 
controls. 




The presence of lipid in the small intestine stimulates secretion of CCK from 
enteroendocrine cells into the circulation. As shown previously, a high-fat meal 
induces more symptoms in FD patients, than an isocaloric high carbohydrate meal 
with a greater concentration of fasting and postprandial plasma CCK compared to 
healthy subjects (115). Therefore, it is possible that lower fat content in the 
carbohydrate rich meal in our study may have caused insufficient CCK excretion. 
Another possible explanation may be that asymptomatic recovered controls had similar 
findings as PI-IBS/FD patients without expressing symptoms. For that reason, a 
healthy control group will be preferable for comparison rather than recovered controls. 
The CCK plasma levels in our PI-FGID patients did correlate with postprandial 
fullness (Paper II), that probably may be mediated by delayed gastric emptying in 
these patients (Paper I). 
 
Long-term alteration of duodenal EC cells, serotonin (5-HT) and cholecystokinin 
(CCK)   
The long-term alteration of duodenal EC cells, 5-HT and CCK in patients with 
persistent abdominal symptoms, after eradicated Giardia infection, were not described 
before.  
The type of infection and the site of maximal injury is important factor in developing 
of clinical picture of PI-IBS. As Giardia trophozoite adhere to the epithelial cells of 
proximal intestine and replicate without invading of intestinal mucosa, we supposed 
that possible changes may taking place in upper GI tract.  
In Paper II, the main outcome was to study duodenal mucosal and plasma serotonin (5-
HT). In addition, we assessed duodenal mucosal and plasma cholecystokinin (CCK).  
We found that PI-IBS/FD patients had significantly decreased number of duodenal 5-
HT containing EC cells, with unaltered 5-HT content, compared to recovered controls. 




In addition, they had decreased duodenal mucosal 5-HT turnover, assessed by mucosal 
5-HIAA ratio. These findings are consistent with IBS-C and PI-IBS patients in study 
performed by Dunlop et al (200). Similar to our findings, an decreased number of 
endocrine duodenal cells, without significant difference in 5-HT content compared to 
controls, was reported in FD patients by Witte et al (223). Other study (224) reported 
significantly higher number of EC cells in post-infectious FD patients compared to 
nonspecific FD or healthy controls.  
Spiller et al (50, 53, 58) showed that PI-IBS patients had increased rectal 5-HT 
containing EC cell counts with increased 5-HT content Although infection resolved, 
the persistent number of elevated EC cells were found in rectal biopsies 3 months after 
Campylobacter infection (53) and in colon biopsies, 3 years after acute Shigella 
infection (2010).  
We found the opposite findings from what we expected. It is possible that decreased 
number of duodenal 5-HT containing EC cells with decreased duodenal mucosal 5-HT 
turnover, assessed by mucosal 5-HIAA ratio after eradicated Giardia infection, could 
be explained by the impaired release of 5-HT or impaired SERT levels.  
Previous studies suggest that inflammation may depress SERT levels. The platelet 
SERT could be a more convenient biomarker for increased serotonin availability.  
Foley et al (225) hypothesized that the changes in SERT induced by low-grade 
inflammation in the duodenum might also alter SERT in platelets. They found that 
IBS-D patients with duodenal immune activation had increased IEL, however normal 
villous had reduced platelet SERT. Dunlop et al (221) found decreased rectal 5 HIAA/ 
5 HT ratio, despite increased 5 HT release, that could be explained by either defective 
SERT or disturbed mono amino oxidase activity. It will be desirable to study SERT 
role in post Giardia FGID patients.   
Increase numbers of mast cells in gastric and duodenal mucosa of FD patients were 
suggested to be the histologic markers of FD (226). Activated colonic mast cells found 




in proximity to colonic nerves may contribute to abdominal pain perception in IBS 
patients (151).  We found no significant difference in duodenal mast cell counts 
between PI-FGID patients and recovered controls (Paper II). Dunlop et al (50) found 
no difference in rectal mast cells in PI-IBS patients when compared to non PI-IBS.  
The further analysis of colonic mast cells could provide more knowledge about their 
role in patients with persisting symptoms after cured Giardia infection. 
 
Long-term alteration of duodenal mucosal T- and B- cells  
In Paper III, duodenal microscopic inflammation was found in a surprisingly high 
proportion (85.7%) of chronic giardiasis patients, 28.8% of PI-FGID and in only a few 
recovered controls. Previous study (227) showed that dyspeptic postprandial 
symptoms and epigastric pain have been associated with duodenal microscopic 
inflammation.  The histological changes induced by Giardia lamblia are non-specific 
(25). The colonic biopsies in chronic giardiasis patients had either normal or only mild 
inflamed ileal mucosa with an increased number of plasma cells and lymphocytes 
(228). As reported previously (4), Giardia positivity was significantly associated with 
pathological histology with the strongest association occurring early after the acute 
infection.   
In our cohort of patients (4), Giardia trophozoite were visible in duodenal biopsies in 
only in 4 (10%) of the 40 cases with Giardia positive fecal samples. In a large study of 
567 giardiasis patients (24), the majority had normal duodenal histology with visible 
Giardia trophozoite in 82.5% of duodenal, but also in antral, jejunal, ileal and colonic 
mucosa.  
When compared histologically normal (H0) with inflamed (H1) biopsies (Paper II), we 
found increased CD20 cell counts, in lamina propria villus and lamina propria crypt in 
PI-FGID patients with microscopic inflammation in an early post infectious period (3-




10 months). Otherwise there were no significant differences between H0 and H1 for 
duodenal CD4 or CD8 cell counts.   
PI-FGID patients from our cohort (Paper III) had predominant IEL CD8+ T cells in 
duodenum as described previously (180). We found no difference in duodenal IEL cell 
count between groups. Similar findings were reported in duodenal mucosa of FD (145) 
and PI-FD (144) patients as well as in rectal mucosa of PI-IBS after Campylobacter 
gastroenteritis (50, 58).  
Our chronic giardiasis patients (Paper III) had decreased lamina propria crypt CD4 + T 
cells, which could be explained by the fact that CD4+ T cells are necessary for 
clearance of the Giardia parasite, as shown in animal studies (229). Surprisingly, the 
persistent decrease in duodenal Lpc CD4 cells counts over time was found in PI-FGID 
but also in recovered controls, gradually increasing to normal levels more than one 
year after the start of giardiasis symptoms. Similar findings were reported by Kindt et 
al (144), who found a reduced number of intravillar CD4 cells in PI-FD without a 
difference in the numbers of IEL when compared to unspecified FD patients. They 
concluded that PI-FD patients showed impaired ability of the immune system to 
terminate the inflammatory response after the acute insult.  
Including recovered control subjects, who were exposed to the Giardia infection at the 
same time, allows a better interpretation of the findings. As lower CD4 cell numbers 
were present in both PI-FGID and RC groups, this finding seems to be a prolonged 
effect of the inflammatory response to gastroenteritis, rather than associated with the 
presence of PI-FGID symptoms.  A study from our group (230) showed that Giardia-
infected individuals in Norway who had presumably acquired the infection while 
traveling abroad had increases in IL-17A, producing CD4 + and as well increased TNF 
production, indicative of a memory T cell response. 
In Paper III, duodenal lamina propria crypt CD20+ cells were elevated in chronic 
giardiasis, FGID and surprisingly in recovered controls up to 19 months after Giardia 




eradication, compared with healthy controls.  Similar findings with increased 
activation of mucosal B-lymphocytes and plasma cells were shown in jejunal biopsies 
in IBS-D patients (231). In Belgium, one year after an outbreak with norovirus, 
Giardia lamblia and Campylobacter jejuni (55), PI-IBS patients had only increased 
rectal B-cell numbers without evidence of persistent immune activation in blood or 
rectal biopsies. The same group showed that rectal biopsies in these patients (232), 
taken 2 years after outbreak showed direct evidence of aberrant neuronal signaling in 
PI-IBS. Surprisingly, this sensitization of gut was not mediated by persistent low-
grade inflammation but appears to be mediated by other pro-nociceptive changes in the 
mucosal microenvironment. 
As previously described, there is a cross-talk between enteroendocrine cells and the 
immune system (233). An animal study showed that secretory products from CD4+ T- 
cells interact with EC to enhance the production of 5-HT in the gut via Th2-based 
mechanisms (158). PI-FGID patients from our cohort had a lower number of duodenal 
EC cells (Paper II) with the decreased counts of duodenal CD4 cells (Paper III) that 
may indicate a temporarily lower 5-HT production. In addition, Lpc CD20 cells (Paper 
III) in PI-FGID patients were positive correlated to EC cells (Paper II) (data not 
shown).  
In Paper III, due to persistent symptoms, repeated duodenal biopsies were taken at two 
time points taken approximately one year apart in 11 Giardia patients. They showed 
increased duodenal lamina propria crypt CD4+ cells and lamina propria crypt CD 8+ 
cells, while Lpc CD20+ B cells showed a declining trend after one year without 
reaching significant difference.  
Persistent symptoms after treated Giardia infection    
After Giardia outbreak in Bergen many patients developed abdominal symptoms, that 
persist for severeal years,  although parasite was eradicated. After an detailed work-up 
and repeated follow-up during the first two years after Giardia infection, we could not 




find out any organic cause that can explain the persisting abdominal symptoms (3). A 
long-term follow-up studies performed in our cohort patients 2, 3, 6 years and 10 years 
after Giardia outbreak (3, 5, 8, 11) confirmed that Giardia infection was associated 
with increased risk of both IBS and chronic fatigue. Therefore, we concluded that 
Giardia may elicit functional gastrointestinal diseases (FGID). A such persisting 
symptoms after cured Giardia infection had not been described before. Searching the 
literature, we found only two studies that reported increased risk of IBS after Giardia 
infection (234) (65). 
The persistent abdominal symptoms may have different causes. The nature of the 
infection has been reported as the strongest predictor of abdominal symptoms 
(235).There is an association between abdominal symptoms with initial severity of 
illness (236) 
The late detection of Giardia infection in Bergen may have contributed that many 
patients developed persistent abdominal symptoms. According to study from our 
cohort (1), it took on average 17 days from onset of illness to the first physician 
contact, and 33 days from illness onset to the treatment start. Only a few patients were 
hospitalized.  
On the other side, many FGID patients did not seek medical help, as the symptoms 
were too weak and unspecific. Sometimes, the stool samples were not sent for 
analysis, since patients had not been abroad, and of those submitted for analysis, many 
samples were not analyzed for Giardia, unless the doctor specifically asked for it. The 
doctors should be aware of such postinfectious sequela following all types of GI 
infection (237). 
Nygaard et al (1) reported that those of our PI-FGID patients, who drank a lot of water 
had a much higher risk for development of symptoms. There was a predominance of 
women (aged 20–29 year), consistent with the previous study report where strongest 
risk factor for developing of FGID was female sex (238). In generally, many patients 




report symptoms aggravation by certain ingested food (239, 240) and the perceived 
food intolerance is a common problem in IBS as reported in cross-sectional study 
performed in Norway (241). 
In our cohort, PI-FGID patients reported symptom worsening due to food intolerance 
(3), that persisted three years after Giardia infection (10).  
The symptoms elicited by Giardia are not specific and could mimic other disease. 
Therefore, it is important to consider coeliac serology since Giardia can elicit 
symptoms that resemble coeliac disease (242, 243). Our group (244) described eight 
cases with elevated coeliac serological markers where six of these later normalized 
after Giardia treatment. Temporary lactose intolerance may also be implicated in 
persisting symptoms after treated Giardia infection (245), although one study (246) 
showed no relationship between bacterial gastroenteritis and persistent lactose 
intolerance. In a small group of PI-FGID patients from our cohort (3), duodenal lactase 
activity was performed without confirming of lactase deficiency. Other possible causes 
of persistent symptoms after Giardia infection can be bile acid disturbance and small 
intestinal bacterial overgrowth (SIBO)(13), but in our cohort patients, symptoms were 
not associated with hydrogen breath excretion after lactulose challenge and cannot be 
related to intestinal bacterial overgrowth (14). 
GI infection and psychological disorders appear to be distinct risk factors, contributing 
additively to the risk of developing both IBS and chronic fatigue syndrome(237). 
Previous studies (247, 248) showed that PI-IBS patients had the higher score for 
anxiety, depression, somatization and neuroticism compared to those who returned to 
normal bowel habits.  
Our PI-FGID patients ( Paper II), is a subgroup of 124 referred patients thoroughly 
investigated after outbreak (3, 4), reported significantly higher score for depression 
(measured by HADs (190), the lower quality of life (measured by The short form  
Nepean Dyspepsia Index-SF-NDI) (192) as well as a tendency to higher neuroticism 




score (measured by Eysenck Personality Questionnaire)(191) compared to post-
Giardia recovered controls.  Increased neuroticism score has previously been reported 
in both FD and IBS (208) and PI-IBS patients (249) compared to healthy controls. Ten 
years after Giardia outbreak in Bergen, Litleskare et al (12) that exposure to Giardia 
infection was associated to a lower quality of life, mainly due to the development of 
IBS and fatigue. 
The increasing levels of anxiety, depression, and somatization are associated with 
higher pre-prandial and/or postprandial GI symptom levels in IBS patients (250) . 
The acute mental stress has been showed to modify visceral perception in both healthy 
controls and IBS patients, but only IBS patients exhibited both altered visceral and an 
exaggerated neuroendocrine response (251). The pre-existing anxiety and 
somatization, investigated in a cohort of over 18 000 people exposed to contaminated 
drinking water (Norovirus, Giardia lamblia, Campylobacter jejuni) (55) were linked to 
a lower immune response and a greater risk of developing GI infection. Of 124 
patients with severe abdominal symptoms, referred to our outpatient clinic 2–18 
months after the Giardia outbreak, approximately 15% reported pre-outbreak slight 
IBS-like symptoms (4) 
 In the prospective study in subjects without previous IBS history who developed PI- 
IBS after Campylobacter gastroenteritis, Spence et al (252) found significantly higher 
levels of perceived stress, anxiety, somatization and negative illness beliefs at the time 
of infection compared to those who did not develop IBS. This study supports 
cognitive-behavioral model of IBS, supported that gastroenteritis may trigger the 
symptoms, but cognitions, behavior and emotions may help to prolong and maintain 
them over time.  
It cannot be ruled out that persistent symptoms in our PI-FGID patients caused 
prolonged stress and health worry which in turn cause prolonged symptoms.  
 




5.6. Strengths and limitations  
One of the main strengths in this study was a well-defined cohort of PI-FGID patients 
who developed persisting abdominal symptoms after a large Giardia outbreak in 
Bergen in 2004. All of them had confirmed Giardia parasite in the stool under 
outbreak, without co-infection, and were successfully treated with metronidazole. The 
inclusion of the relatively large number of patients allowed a description of duodenal 
mucosal lymphocytes kinetics. Repeated biopsies, even in a small number of PI-FGID 
patients, allowed us to follow up these patients over time.  One of the limitations in 
this thesis, is that we did not assess ROMA scores in some PI-FGID patients at the 
start of initially work up. Healthy controls were not included at the same time as PI-
FGID patients and recovered controls.     
 
5.7. Conclusions and future perspectives   
The patients with persisting abdominal symptoms after cured Giardia infection, 
showed increased visceral sensitivity with delayed gastric emptying assessed by 
ultrasound in combination with low-caloric meal soup. The 5-HT3 antagonist 
(Ondasentron®) influenced only postprandial nausea without improving of drinking 
capacity, 3D volumes, or gastric emptying.  
PI-FGID patients had lower fasting and postprandial plasma 5-HIAA and CCK plasma 
levels in PI-FGID group correlated to fullness and bloating. PI-FD/IBS patients had 
reduced duodenal 5-HT containing EC cell count. There was a correlation between 
duodenal EC cell numbers and mucosal 5-HT content.  
Only a few patients had a sign of microscopical duodenal inflammation. Duodenal 
lamina propria crypt (Lpc) CD20+ cells were persistently elevated, longer than 19 
months, in all three Giardia exposed groups, compared to healthy controls.  




Duodenal EC cell counts did correlate to persisting decrease duodenal Lpv CD4 and 
Lpc CD4 cells. This may indicate a temporarily lower 5-HT production that could be 
associated with ongoing immune activation.  
We believe that interactions involving Giardia and gut microbiota may cause persistent 
dysbiosis that may have predisposed for persistent visceral hypersensitivity.   
Further research highlighting the emerging immune-endocrine axis interaction with 
intestinal microbial dysbiosis caused by Giardia, as a potential target for therapeutic 
strategies in FGID, is warranted. 
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Increased visceral sensitivity in Giardia-induced
postinfectious irritable bowel syndrome and functional
dyspepsia. Effect of the 5HT3-antagonist ondansetron
V. DIZDAR,* O. H. GILJA*, & T. HAUSKEN*,
*Institute of Medicine, University of Bergen, Bergen, Norway
National Centre for Ultrasound in Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
Abstract In an outbreak of waterborne giardiasis
where 1300 subjects were diagnosed, with Giardia
lamblia, 139 continued to have abdominal symptoms
of whom two of three had negative stool culture and
microscopy. These were considered to have a postin-
fectious functional gastrointestinal disorder. We
investigated visceral hypersensitivity in patients with
persisting abdominal symptoms after Giardia infec-
tion and assessed the effect of 5HT3-antagonist
ondansetron. Twenty-two patients with Giardia neg-
ative stools and 19 controls were included. A subset of
patients (n = 15) had both irritable bowel syndrome
(IBS) and functional dyspepsia (FD). All subjects
underwent a satiety test with a soup combined with
three-dimensional ultrasound. Fifteen of 22 patients
underwent double-blind, randomized, placebo-con-
trolled study with the 5-HT3 antagonist ondansetron
given orally. Drinking capacity was lower in patients
than in controls (P < 0.01) and gastric emptying was
reduced (P < 0.05). Patients had more symptoms both
fasting and postprandially (P < 0.001) compared to
controls. Ondansetron had no effect on these param-
eters except from less nausea postprandially (P < 0.05).
In conclusion, patients with Giardia-induced gastro-
intestinal symptoms developed both IBS and FD. They
exhibited gastric hypersensitivity with lower drinking
capacity and delayed gastric emptying. The 5-HT3
antagonist ondansetron did not improve drinking
capacity, gastric emptying or symptoms except
nausea.
Keywords 5-HT3 antagonist, functional dyspepsia,
Giardia, irritable bowel syndrome, postinfectious,
visceral hypersensitivity.
INTRODUCTION
In 2004 an extensive outbreak of waterborne giardiasis
occurred in Bergen, the first large outbreak of a
waterborne parasitic disease ever recorded in Norway.1
In this period, 1300 cases were confirmed to have
Giardia by stool examination. The most prominent
clinical signs in these patients were abdominal pain,
nausea, bloating and loose stools. Most patients were
treated with metronidazole by their general practitio-
ners. However, in 139 of them, symptoms persisted
even after several treatment courses with metronida-
zole. In two-third of patients with persisting symp-
toms, no Giardia cysts were found in stools and they
were thus considered to have Giardia-induced post-
infectious functional gastrointestinal disorders (PI-
FGID). Long lasting persisting GI symptoms in
post-treatment cyst-negative Giardia patients have to
our knowledge not previously been reported in a
similar scale.
The prevalence of PI-IBS (irritable bowel syndrome)
after Salmonella, Shigella and Campylobacter gastro-
enteritis varies from 7% to 31%.2 In PI-IBS after
Campylobacter jejuni infection, Dunlop et al.3 found
increased number of serotonin (5-hydroxytriptamine,
5-HT) containing enterochromaffin (EC) cells with
abnormalities in serotonin metabolism and persistent
low-grade bowel wall inflammation. Three months
after infection, these patients had increased the gut
transit and enhanced visceral sensitivity.4 Previous
studies have shown that the 5-HT3 antagonist could
improve upper and lower GI symptoms in patients
with functional dyspepsia (FD) and IBS.5–12 As visceral
hypersensitivity is proposed as biological marker of
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both FD and IBS, we hypothesized that abnormal
serotonin metabolism was involved in developing of
postgiardia symptoms and that 5-HT3 antagonists
could improve visceral hypersensitivity and sym-
ptoms.
Ultrasonography in combination with a low caloric
meal is used to study gastric motility,13 accommo-
dation14–18 and gastric emptying19 in FD patients.
Drink tests with high or low caloric drinks, as a
non-invasive test to study visceral sensitivity and
gastric accommodation in upper GI tracts, has been
developed.20,21 When using a low caloric drink test in
combination with three-dimensional (3D) ultrasonog-
raphy of the stomach, an optimal discrimination
between FD patients and controls was obtained
by the combination of symptoms and intragastric
volume.22
The aims of this study were to investigate visceral
hypersensitivity of the upper GI tract in patients with
postinfectious Giardia-induced abdominal symptoms
using a drink test combined with 3D ultrasonography
and to assess the effect of 5HT3-antagonist ondanse-
tron in these patients.
MATERIALS AND METHODS
Study subjects
Twenty-two patients [M/F 10/12, 45.5%/54.5%, med-
ian age 33, range 20–50, mean body mass index (BMI
23 ± 2.9)], with persisting abdominal symptoms
12 months after Giardia infection were consecutively
included from our Giardia outpatient clinic. In the
large group of 139 individuals, median age was 31
(range 16–79 years), 38.8% was men and 61.2%
women. Accordingly, this indicates that our study
population was representative of the whole population
(n = 139) with continuous symptoms.
Subsequently, they were examined with blood tests,
stool culture and microscopy, upper endoscopy and
duodenal biopsies. None of them had Giardia cysts or
other microorganisms in faecal samples at the time of
study. None was taking any medication during the last
2 weeks before the start of the study. All patients
fulfilled the ROME II criteria for the IBS.23 Fifteen
patients also had symptoms compatible with the
diagnosis of FD.24
Before inclusion into the study, a medical history
was obtained, and ultrasound of the liver, pancreas and
biliary tract was performed to rule out other diseases of
the upper GI system. Criteria of exclusion from the
study were serious systemic or suspect malignant
disease, previous surgery in the upper GI tract,
previous peptic ulcer disease, alcoholism, diseases of
the liver, pancreas or bile ducts, pregnant or lactating
women, or subjects using any medication.
As controls served 19 young, healthy persons (M/F
10/9, median age 31, range 22–45, mean BMI 24 ± 3.8),
who had Giardia infection at the same time but
recovered rapidly from symptoms after one-to-two
courses with metronidazole. Control subjects were
asymptomatic at the time of inclusion. They under-
went a general medical examination with blood tests,
stool culture with microscopy and gastroscopi with
duodenal biopsies.
Fifteen, of totally 22, consecutive patients (M/F 9/6,
median age 35, range 21–51, mean BMI 23 ± 2.5) agreed
to undergo a double-blind, randomized, placebo-
controlled study with 5-HT3 antagonist ondansetron.
The effect of ondansetron on visceral hypersensitivity
was evaluated with a drink test in combination with
3D ultrasonography.
Study design
The participants were examined between 08:00 and
10:00 hours after an overnight fast. The subjects
ingested meat soup, 100 mL every minute, until
maximal drinking capacity and the volume of the
stomach was then assessed using 3D ultrasound. All
investigations were made while the individuals were
breathing normally, sitting in a chair, leaning slightly
backwards at an angle of 120. Abdominal symptoms
were assessed both fasting and at maximal drinking
capacity.
Patients receiving ondansetron were studied on two
separate occasions, with 7–14 days interval between
examinations. They received oral treatment with
either ondansetron, 8 mg or placebo, 20 p.m. the day
before and the next day 1 h 30 min before the drink
test. Placebo and study medication (Zofran; Glaxo
SmithKline) were identical in appearance. Study sub-
jects and the clinical investigators were blinded to the
treatment assignment until the data analysis was
completed.
Test meals
The test meal was commercial available meat soup
(Toro clear meat soup; Rieber & Søn A/S, Bergen,
Norway). The soup contained 1.8 g protein, 0.9 g fat,
1.1 g carbohydrate and non-soluble seasoning (0.2 g)
per 500 mL (4 kcal 100 mL)1). The pH of the soup
varied between 5.4 and 5.7, and the osmolarity was
350 mOsm kg)1 H2O. The soup was first boiled and
then cooled to 37 C.
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Ultrasonography
Three-dimensional ultrasound imaging was per-
formed with a Loqic 9 scanner (GE Medical Systems,
Milwaukee, WI, USA) with a 3,5 MHz transducer inter-
faced to a magnetic position and orientation measure-
ment system. The Bird system (Ascension Technology
Corp., Burlington, VT, USA) was calibrated before each
3D acquisition that was performed at maximal satiety.
The recording was stored on a PC workstation for later
analysis using dedicated software (Echopac3D, Horten,
Norway). This acquisition procedure and software have
demonstrated very good accuracy in volume estima-
tion.17,25 All examinations were performed by the same
doctor (TH) to avoid differences in intraobserver varia-
tion. All gastric volume measurements were performed
blinded (by VD) after study completion. Gastric empty-
ing (GE %), measured once – after meal, was defined as
the fraction of the meal emptied from the stomach
immediately after meal [(drinking capacity ) intraga-
stric volume)/drinking capacity · 100%)].
Symptoms
Abdominal pain/discomfort, nausea, fullness and sati-
ety were assessed using a visual analogue scale (VAS), a
100 mm unmarked line where 0 expressed no symp-
toms and 100 expressed excruciating symptoms.
The sum of the scores for nausea, fullness and pain
at maximal drinking capacity was denoted as the
pooled symptom score.
Ethics approval
The protocol was approved by the Regional Committee
for Research Ethics, Bergen, Norway. All participants
gave written informed consent to participate in the
study.
Statistical analysis
Data are presented as a mean values or mean ± SD.
Variables were analysed using parametric (paired- and
unpaired Students t-test as appropriate) or non-para-
metric (the Wilcoxon‘s or Mann–Whitney test as
appropriate).
Correlations were assessed using Pearson correla-
tions coefficient. Significance was accepted at the 5%
level. We expect an improvement in drinking capacity
of 200 mL soup as effect of treatment and calculated
that a minimum of 15 subjects were required to have a
power of 0.80 assuming P-value <0.05. All statistical
analyses were performed with Prism 4.0 (Graph Pad
Software Inc., San Diego, CA, USA) and SPSS 14.0 for
Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
All 22 patients with persisting abdominal symptoms
after Giardia infection fulfilled ROME-II criteria for
diarrhoea-predominant IBS and 15 of 22 had overlap-
ping FD.23,24 None of the study subjects had abdominal
symptoms prior to the onset of acute giardiasis.
In fasting state, patients had more abdominal pain
(P < 0.001), discomfort (P < 0.001), nausea (P < 0.01)
and fullness (P < 0.001) compared to controls. More-
over, postprandial pain (P < 0.001) and discomfort
(P < 0.001) were significantly higher in patients than
in controls (Fig. 1). Pooled symptom scores were
significantly higher in patients compared to controls
both before (P < 0.001) and after meal (P < 0.001).
Drinking capacitywas lower in patients than controls
(795.5 ± 370.9 mL vs 1295 ± 765.6 mL respectively;
P < 0.01) (Fig. 2). Similarly, intragastric volumes were
lower in patient compared to control group
(509.1 ± 186.9 vs 683.4 ± 342.2 mL respectively;
P < 0.05) (Fig. 3). Gastric emptying was significantly
reduced in patient compared to controls (30.6 ± 18.02%
vs 43.8 ± 12.3% respectively; P < 0.01) (Fig. 4).
Nausea was significantly negatively correlated to
maximal ingested drinking volume (r = )0.48;
P < 0.05) and total gastric volume (r = )0.54;
P < 0.05). Fullness (r = 0.47; P < 0.05) and satiety
Figure 1 Dyspepsia symptoms, scored on visual analogue
scale, 0–100 mm, (P < 0.01), before and after the soup drink
test in 19 controls and 22 patients with Giardia-induced
postinfectious irritable bowel syndrome/functional dyspepsia.
Values are expressed as mean ± SD; Mann–Whitney test.
The figure shows only significant symptoms score.
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(r = 0.45; P < 0.05) were significantly positively corre-
lated to total gastric volume at maximal satiety.
There was no significant difference between sub-
groups IBS + FD vs IBS for drinking volumes, gastric
emptying and 3D volumes. However, patients with
overlapping IBS + FD experienced more fullness before
ingestion of meal (P < 0.05) compared to those with
only IBS (Fig. 5). No significant differences were found
between groups for other symptoms or gastric volumes
(results not shown).
Effect of ondansetron
Twelve of 15 patients had both IBS and FD and three
had IBS only. There were no significant differences
between the ondansetron and placebo group neither for
drinking capacity (900 ± 358.6 mL vs 813.3 ±
264.2 mL; P = ns), 3D volumes (490 ± 191.7 mL vs
500 ± 216.7 mL; P = ns) and gastric emptying
(43.16 ± 22.30 mL vs 38.07 ± 18.71 mL; P = ns). How-
ever, nausea score postprandially was significantly
lower in the treatment group compared to placebo
group (27.47 ± 21.89 vs 41.40 ± 23.04; P < 0.05) (Fig. 6).
Otherwise, there were no significant differences for
pain, nausea, fullness, satiety and sum symptoms
before or after drinking test in the ondansetron group
compared to placebo group (results not shown).
DISCUSSION
We found that patients with persisting abdominal
symptoms after Giardia infection had enhanced
visceral sensitivity after meal ingestion with reduced
Figure 2 Maximal drinking capacity (mL) in 19 controls and
22 patients with Giardia-induced postinfectious irritable bo-
wel syndrome/functional dyspepsia. Patients had significantly
lower maximal ingested volume than controls (P < 0.001).
Horizontal bar represents mean.
Figure 4 Gastric emptying (%) after soup ingestionwasmuch
slower in 22 patients withGiardia-induced postinfectious
irritable bowel syndrome/functional dyspepsia compared to
19 controls (P < 0.01). Horizontal bar represents mean.
Figure 5 Fullness before drink test in 22 patients with per-
sistent abdominal symptoms after Giardia infection. Sub-
group analyse showed that 15 patients had overlapping
irritable bowel syndrome (IBS) + functional dyspepsia (FD) and
seven had only IBS. There was no significant difference in
symptoms between subgroups except more fullness before
meal in IBS/FD subgroup (P < 0.03).
Figure 3 Intragastric (3D) volumes (mL) measured after
maximal soup ingestion in 19 controls and 22 patients with
Giardia-induced postinfectious irritable bowel syndrome/
functional dyspepsia. Patients had lower 3D volume compared
to controls (P < 0.05). Horizontal bar represents mean.
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drinking capacity, delayed gastric emptying and signif-
icantly more postprandial symptoms compared to
controls. This view is supported by a previous study
showing that bacterial GI infection is a significant risk
factor not only for IBS but also for Dyspepsia.26
Furthermore, hypersensitivity to gastric distension,
delayed gastric emptying and impaired accommodation
was found in acute-onset FD.27 Accordingly, postin-
fectious IBS and FD seems to be a real condition
affecting a substantial number of patients, at least after
infection withGiardia lamblia. As the major habitat of
Giardia trophozoites is in the duodenum and 15 of 22
of our patients developed dyspepsia in addition to IBS,
we hypothesized that these patients had visceral
hypersensitivity in the upper GI tract.
Investigation of visceral perception in humans is
based primarily on distension test where the elec-
tronic barostat remains as a gold standard.28 However,
this technique is invasive, unpleasant and influences
gastric physiology.17,29 Drink tests have been pro-
posed as a more physiological and non-invasive way
to test visceral hypersensitivity and were found to be
highly reproducible and well correlated with barostat
measurement.21 Furthermore, ultrasonography is
widely available, applicable for scanning of the stom-
ach and can easily be combined with a drink
test.16,22,30 Perception of fullness and satiety was
significantly positively correlated to 3D volume,
which suggested that distension of the stomach
induce fullness and satiety. These results suggest that
triggering of mechanoreceptors may generate symp-
toms. The perception of postprandial nausea in our
study was negatively correlated to maximal drinking
volumes, which indicates that nausea inhibits maxi-
mal drinking capacity to be reached. Liquid meal
appears to enter the duodenum within 1 min postp-
randially, before the occurrence of symptoms, which
suggests that tasting of ingested material by intesti-
nal chemo-receptors may be involved in symptom
generation.17,31 We found that patients with Giardia-
induced persisting abdominal symptoms had a signif-
icantly lower emptying rate of liquid meal than
controls. Delayed gastric emptying has been reported
both in IBS and FD, although conflicting results
exists. Stanghellini et al.32 showed that 66% of IBS
patients had overlapping dyspepsia where this group
had significant lower gastric emptying of solids,
evaluated by scintigraphy, compared to IBS without
overlapping dyspepsia.
Postinfectious IBS is associated with increased sero-
tonin (5-HT)-containing EC cells,33 which are found
throughout the GI tract, most in proximal duodenum
and rectum. 5-HT3 receptors are located peripherally
on the parasympathetic terminals and centrally in the
central nervous system (CNS). Feinle and Read9 inves-
tigate involvement of 5-HT3 antagonist in gastric
motor and sensory response to distension, using gastric
barostat and lipid infusion, and found that ondansetron
reduced nausea and gastric sensitivity to distension.
Moreover, 5-HT3 antagonist was found to reduce
postprandial symptoms10–12 and gastric emptying5 in
both healthy subjects and FD patients. However, 5-HT3
antagonists have mainly been used in IBS and showed
to relax colon, delay colon transit and improve symp-
toms of diarrhoea-predominant IBS.6–8,11
In our study, however, ondansetron reduced only
nausea after meal compared to placebo, but had no
significant effect on other symptoms or drinking
capacity, intragastric volume and gastric emptying.
Serotonin is a key mediator in signalling to the CNS,
via 5-HT3 receptors, and acts as a major cause of nausea
and vomiting associated with cancer chemotherapy34
and abdominal surgery. Although we had a small
number of patients and type 2 error cannot be
excluded, the results from our study argue against an
important role of serotonin in generation of dyspeptic
symptoms in postgiardiasis. The effect of ondansetron
on postprandial nausea can possibly be explained by
central mechanisms.
In conclusion, we found that most patients with
Giardia-induced postinfectious GI symptoms devel-
oped both FD and IBS with enhanced visceral sensitiv-
ity due to lower drinking capacity and delayed gastric
emptying assessed by a 3D ultrasound drink test.
However, 5-HT3 receptors did not appear to be involved
in pathogenesis of dyspeptic symptoms in patients
with postinfectious Giardia-induced IBS and FD.
Figure 6 Influence of ondansetron on meal induced nausea
in the 15 patients with Giardia-induced postinfectious
irritable bowel syndrome/functional dyspepsia. There was
significantly less nausea, after meal ingestion, in ondansetron
group compared to placebo group (P < 0.03). Horizontal bar
represents mean.
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Post-infectious irritable bowel syndrome (PI-IBS) and functional dys-
pepsia (FD) have been described after both Campylobacter jejuni gastro-
enteritis and Giardia infection. After C. jejuni, there is increased rectal
serotonin (5-HT)-containing EC cells and postprandial plasma 5-HT,
while a pilot study suggested increased plasma cholecystokinin (CCK)
after Giardia infection.
Aim
To determine changes in plasma and duodenal mucosal 5-HT and CCK
in Giardia-induced PI-IBS.
Methods
A total of 32 patients previously infected with Giardia and 19 who
had recovered fully (controls) completed symptom questionnaires.
Endoscopic duodenal biopsies were obtained from all subjects and
immunohistochemically stained for CCK, 5-HT and CgA containing entero-
endocrine cells and mast cells. 5-HT content was also assessed. Twenty-one
of 32 patients and 19 controls consumed a high-carbohydrate meal, while
fasting and postprandial plasma CCK and 5-HIAA were measured.
Results
Post-infectious irritable bowel syndrome patients had increased numbers
of CCK cells (P = 0.02), but lower numbers of EC cells (P = 0.009).
Plasma CCK did not differ significantly between the groups, but corre-
lated significantly with postprandial dyspepsia scores (r = 0.5, P = 0.05).
PI-IBS patients had significantly lower plasma 5-HIAA, before and after
meal (P = 0.05) as well as more dyspepsia (P < 0.0001) compared with
recovered subjects.
Conclusions
Post-infectious bowel dysfunction following Giardia infection is associ-
ated with increased duodenal mucosal CCK. Postprandial dyspeptic
symptoms correlate better with CCK than measures of 5-HT metabolism.
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INTRODUCTION
Irritable bowel syndrome (IBS)1, 2 and functional dys-
pepsia (FD)3 may follow acute intestinal infection and
can persist for months or years.4 Animal studies had
shown that long-term bowel dysfunction can develop
after a transient gastrointestinal infection.5 Human
studies following Campylobacter jejuni enteritis have
shown persistent low-grade rectal mucosal inflamma-
tion with increased number of lamina propria T lympho-
cytes, increased number of enterochromaffin (EC) cells,
increased serotonin bioavailability and increased small
intestinal permeability in post-infectious IBS (PI-IBS).2
However, the clinical features of post-infective bowel
dysfunction appear to depend on the type of infection
and the site of maximal injury. Thus, rotavirus gastro-
enteritis which predominantly affects the upper gut is
followed by delayed gastric emptying;6 Shigella enteri-
tis affects mainly the left colon causes post-infectious
IBS (PI-IBS),7whereas Salmonella enteritis which causes
both terminal ileal and proximal colonic ulceration
causes both functional dyspepsia and PI-IBS.4 Previous
studies of bacterial enteritis suggested that an increase
in serotonin-containing EC cells was a feature after
Campylobacter enteritis, but other sorts of enteroendo-
crine cells such as the PYY-containing cells showed a
different profile causing a switch in the normal PYY ⁄
5-HT ratio.2 Other infections such as H. pylori elicit a
different response with a decrease in somatostatin-
containing enteroendocrine cells, but an increase in
those containing gastrin.8 We also found in mice
infected with Trichinella spiralis that while the numbers
of 5-HT-containing EC cells increased in the duodenum,
they actually decreased significantly in the colon and
hence it appears that the effect of infection on ente-
roendocrine cells in the gut is complex and depends on
both site and type of organism.9
A recent prospective cohort study performed in
Giardia lamblia-induced PI-IBS patients10 concluded
that many previously healthy persons experienced per-
sisting abdominal symptoms after a large waterborne
outbreak of giardiasis in Bergen, Norway. Over a 15-
month period, 124 referred patients were evaluated
and frequent findings were chronic Giardia infection
and microscopic duodenal inflammation, especially if
the evaluation was less than 7 months from the initial
illness. Diarrhoea, bloating, nausea, abdominal pain,
duodenal mucosal inflammation and elevated levels of
faecal calprotectin suggest increased inflammatory
response in these patients; however, as time went by,
we started seeing more patients in whom the Giardia
parasite had been eradicated, yet symptoms persisted.
A previous pilot study had suggested that increased
plasma cholecystokinin (CCK) can occur following
acute Giardia infection and might mediate the anor-
exia often associated with this.11 The aim of our study
was therefore to determine the importance of duodenal
serotonin (5-HT) and CCK containing cells as well as
plasma 5-HT and CCK in patients with prolonged
abdominal symptoms after successful treatment of the
Giardia infection. We hypothesized that altered 5-HT
and CCK signalling would be associated with the
development of Giardia-induced PI-IBS.
MATERIALS AND METHODS
Study subjects
Altogether, as previously described,10 there were 124
proven cases of giardiasis referred to hospital because
of persisting symptoms, mostly bloating and diarrhoea,
despite adequate treatment with metronidazole. Forty
still had Giardia infection leaving 84 cases of post-
giardiasis. The 32 consecutive patients included in the
current study (see Flow chart, Figure 1) were a sub-
group of these 84. All had completed one or more
anti-Giardia treatment courses and microscopy of later
stool samples had been repeatedly negative. After an
elaborate clinical workup, they had received a diagno-
sis of PI-IBS and they met the ROME II criteria for
IBS.12 Twenty one patients also had symptoms com-
patible with the diagnosis of FD.13
The control group consisted of 19 healthy persons,
without abdominal or other complaints who had Giar-
dia infection at the same time as patients, but recov-
ered rapidly from symptoms after 1–2 courses with
metronidazole. These subjects were not referred to our
out-patient clinic, but recruited via phone to partici-
pate in the study. They had normal endoscopy of the
upper GI tract. None of the study participants had pre-
vious gastrointestinal surgery (other than appendec-
tomy or cholecystectomy), pregnancy, history of drug
or alcohol dependence, other significant illness, or any
medication that may alter GI motility (as serotonin
reuptake antagonists, TCA and opiates).
Carbohydrate rich test meal
Blood samples were taken for measurements of fasting
and postprandial platelet poor plasma (PPP) 5-HT and
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plasma CCK, whereas platelet 5-HT (platelet-rich plas-
ma)(PRP) was measured at baseline only. The subjects
then ingested test meal within 15 min ()15 to 0 min)
and samples for plasma 5-HIAA and CCK were taken
immediately after meal ingestion (time 0) and every
30 min for 4 h postprandially (time 30, 60, 90, 120,
150, 180, 210, 240). We used a similar carbohydrate-
rich meal as Houghton et al.,14 which consists of
100 g boiled pasta in 100 mL tomato soup (Toro, Rie-
ber&Søn, A ⁄S Bergen, Norway), 50 g white bread (two
slices), 8 g soft margarine, one wheat bun,10 g jam
(500 g sugar ⁄kg) and 300 mL tap-water (calorie con-
tent of 557 kcal – carbohydrates, 63%; fat, 27%; pro-
tein, 10%).
Assessment of dyspepsia score
Abdominal symptoms (abdominal pain ⁄discomfort,
nausea, fullness and bloating) were assessed before
(time )30 min) and every 30 min after meal up to 4 h
postprandially by using the ROME II dyspepsia ques-
tionnaire.13 Subjects were asked to score the severity
of symptoms using the scale 0 = none; 1 = mild;
2 = moderate; 3 = severe. The overall postprandial
dyspepsia score was calculated by adding the total
scores for each of the four symptoms over the 4-h
postprandial period (0–96).
Blood samples for serotonin (5-HT) and
cholecystokin analysis
The subjects were asked to refrain from serotonin-rich
food for 72 h, and alcohol and nicotine 24 h prior to
the study. They arrived at 8 AM after on overnight fast
and an 18 guage cannula was inserted in the antecu-
bital vein. Blood samples were taken with the volun-
teers in a sitting position without using a tourniquet
as previously described.14 A three-way tap was
attached to the cannula and the system was flushed
with 2.5 mL of sterile normal saline containing hepa-
rin 10 units per mL. After every blood sample, the
cannula was flushed with heparinised saline to prevent
platelet activation. Blood samples were collected into
pre-chilled 5 mL plastic syringes containing 0.45 mL
of citrate-dipyridamole-adenosine-theophylline (CTAD)
platelet stabilizing solution (Diatube H vacutainer
tubes, Becton-Dickinson, Franklin Lakes, NJ, USA).
During blood withdrawal, care was taken to ensure
smooth rapid blood flow while avoiding excessive tur-
bulence. The blood-anticoagulant mixture was placed
immediately into the empty vacutainer from which the
anticoagulant had been withdrawn, the lid was
replaced and the sample was placed on ice. Following
blood sampling, the intravenous cannula was flushed
with 2.5 mL of normal saline containing 10 units of
Post-giardiasis patients
Post-giardiasis recovered controls





median age 31 years (range 22–45)
Carbohydrate rich meal
median age 30 years (range 24–39)
(formalin fixed biopsies)
(snap frozen biopsies)
(plasma 5-HIAA and CCK)
(n = 19)
recruited at hospital follow up (n = 32)
Three patients excluded
Not lab-confirmed giardiasis (n = 2)
Missing value (n = 1) Dropped out
    (n = 1)
dropped out
    (n = 1)
Missing value 
     (n = 1)
Recovered controls
         (n = 19)
   Recovered
controls (n = 19)
    Recovered
controls (n = 19)
Diagnosed gastric ulcer (n = 1)
PI-IBS/FD patients
 included (n = 29)
   PI-IBS/FD
patients included
     (n = 18)
   PI-IBS/FD
patients included
     (n = 21)
Eligible PI-IBS/FD patients (n = 29)
             Analysis of
duodenal EC cells, CCK cells,
   mast cells and CgA count
           Analysis of
duodenal 5-HT & 5-HIAA
Figure 1. A flowchart of post-giardiasis PI-IBS ⁄ FD patients and recovered controls with duodenal histology analysis and
meal test.
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heparin per mL. Between sampling, the subjects rested
and were kept warm to ensure good peripheral blood
flow.
Preparation of platelet-poor and platelet-rich
plasma
Platelet-poor plasma was produced in a single step by
centrifuging the vacutainer tubes at 3500 · g for
25 min at 4 C within 5 min of being taken. Platelet-
rich plasma was prepared separately by centrifugation
at 320 · g for 10 min at 4 C. Samples were removed
promptly from the centrifuge and 1 mL of plasma was
removed from the middle third of the supernatant
using a plastic pipette and placed into polypropylene
cryotubules. A 200 lL sample of platelet rich plasma
was sent to the Department of haematology and plate-
lets were counted using an automated cell counter
(Sysmex, Kobe, Japan). All samples were frozen imme-
diately at )80 C and analysed in batches within
3 months of collection.
Extraction of 5-HT from biopsy sample and
analysis of 5-HT and 5-HIAA by HPLC
This procedure was performed as previously
described.15 In brief, 5–10 mg of tissue was homo-
genized in perchloric acid, centrifuged and the super-
natant contents analysed using HPLC with
electrochemical detection. The limit of detection for
5-HT and 5-HIAA was 4 and 1 nmol ⁄L and the coeffi-
cient of variation for the method was 0.8% and 2.1%
respectively. Fasting platelet-rich plasma (PRP) samples
were analysed for 5-HT while postprandial platelet-
poor plasma (PPP) samples were analysed for 5-HIAA
using the same technique. We chose to analyse plasma
5-HIAA as it shows a smoother postprandial profile
rising steadily and avoids the problems of artifactually
high 5-HT due to platelet activation. We therefore
analysed plasma 5-HIAA, fasting ()30 min), immedi-
ately after meal (0 min) and at the end of the meal
(210 and 240 min) as previous data from ourselves
and others show that 5-HIAA rises steadily during 4 h
postprandially.15, 16
Duodenal biopsy specimens
Gastroduodenoscopy was performed in 32 patients
with Giardia-induced PI-IBS ⁄FD and 19 recovered
controls under fasting conditions on a separate day
from the meal test. A total of six biopsy specimens
were taken from the distal part of duodenum during
endoscopy. Three biopsy specimens were placed in 4%
buffered formalin for routine histological analysis.
Three biopsies were snap frozen in liquid nitrogen and
then stored at )80 C and analysed for 5-HT and 5-
HIAA content. A standard technique was used to pre-
pare each biopsy for immunohistochemistry for seroto-
nin producing enterochromaffin (EC) cells, as
previously described,15 CCK producing enteroendocrine
cells,17 mast cells and the nonspecific marker for all
enteroendocrine cells, Chromogranin A (CgA).
Immunocytochemistry and image analysis
Nucleated 5-HT-containing cells were counted on
coded slides within four non-overlapping high pow-
ered fields. Staining was performed using previously
described methods9 using rabbit antihuman serotonin
antibody (Serotec Ltd, Oxford, UK) and the AvidinBio-
tin technique counterstained with haematoxylin. Cells
were counted using the Weibel 2 graticule method as
previously described and results expressed as cells per
mm2. Mucosal mast cells were stained for their chloro-
acetate esterase activity using the substrate napthol
AS-D chloroacetate and the diazonium salt pararosani-
line as previously described,18 slides were then count-
erstained in Mayer’s haematoxylin and counted using
the Weibel graticule.9 All enteroendocrine cells were
stained for the nonspecific marker Chromogranin A
(CgA) using rabbit Chromogranin antibody followed
by biotinylated swine anti-rabbit antibody followed by
AvidinBiotin Complex incubated with diaminobenzi-
dine tetrahydrochloride (DAB) to develop a brown pig-
ment counterstained with haematoxylin (DAKO,
Cambridge, UK).
The antiserum against CCK used in this study is
directed against gastrin ⁄CCK, C- terminus, cross-react-
ing with both gastrin and CCK. The cells identified by
this serum are mostly CCK cells, as the human duode-
num is the main location for CCK cells, with few gas-
trin cells.19 CCK immunoreactive cells were detected
by Avidin Biotin Complex (ABC) method counter-
stained with haematoxylin, as described earlier in
details,17 using rabbit antihuman gastrin ⁄CCK anti-
body (EuroDiagnostica, 804630, Malmö, Sweden).
We used different quantification method for CCK
cells.20 Morphometric analysis for CCK ⁄gastrin, C- ter-
minus immunoreactive cells was performed using
Olympus program ‘Cell P’, with a x 40 objective and
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in a frame representing an area of 0.13 mm2 of the
tissue. The number of nucleated CCK cells in the crypts
was counted in coded slides from 20 randomly chosen
fields from three different sections from each individ-
ual. All measurements were performed by the same
person (V.D.) and double-checked by an experienced
person (M.E.S.).
Questionnaires
Nineteen recovered controls and 21 PI-IBS ⁄FD patients
completed a validated Norwegian version of the ROME
II questionnaires,12 HAD (Hospital Anxiety and
Depression Scale)21 and EPQ-N (Eysenck Personality
Questionnaire, short 12-item scales).22 In addition,
14 ⁄21 PI-IBS ⁄FD patients and 14 ⁄19 recovered con-
trols completed the short form Nepean Dyspepsia
Index (SF-NDI).23 SF-NDI includes five subscales (ten-
sion, interference with daily activities, eating ⁄drinking,
knowledge ⁄ control and work ⁄ study). The items were
measured by a Likert scale from 1 to 5 and total sum
score for each of the five subscales was calculated by
adding up scores for each item.
Data and statistical analysis
Demographic data are shown as median (range). Group
differences are expressed as the mean + SEM, when dis-
tributed normally, otherwise median value  interquar-
tile range is given. Differences between groups were
measured using the unpaired t-test (for parametric data)
or Mann–Whitney (for non-parametric data). CCK con-
centrations in plasma were calculated as the area under
the postprandial concentration curve (AUC) vs. time.
Previous studies11 suggest a mean difference in peak
CCK of 10 pM ⁄L (s.d. 10) and hence we calculated that
we would require 17 in each group to achieve a power
of 80% to detect such a difference. Dyspepsia score was
calculated as the AUC of the total score. Relationship
between dyspepsia scores and CCK or 5-HIAA was cal-
culated using linear regression analysis. A P-value £
0.05 was considered significant. Data were analysed
using GRAPH PAD PRISM 4 (San Diego, California, USA)
and SPSS 14.0 (Chicago, Illinois) for Windows.
Ethics approval
The Regional Committee of Research Ethics approved
the study and all subjects gave written informed con-
sent to participate in the study.
RESULTS
Assessment of dyspepsia score
We found that 16 ⁄20 (80%) of patients and 5 ⁄19
(26%) recovered controls reported mild symptoms
immediately before meal ingestion (P for differ-
ence = 0.01). PI-IBS ⁄FD patients had significantly
higher total postprandial symptom score (AUC) for
pain (P < 0.005), nausea (P < 0.0001), fullness
(P < 0.0001) and bloating (P < 0.0001) compared with
recovered controls (see Table 1). None of the partici-
pants reported ‘severe’ symptoms postprandially.
Psychiatric questionnaires
Post-infectious irritable bowel syndrome ⁄ functional
dyspepsia patients had a significantly higher score for
depression (HAD-D, 5.2  1.0 vs 2.3  0.5, P = 0.02)
and lower quality of life (SF-NDI, 31.4  1.9 vs
10.7  0.5, P < 0.0001) compared to controls. There
was a tendency to higher neuroticism scores in the PI-
IBS ⁄FD group, but this did not reach significance
(P = 0.06).
Plasma and platelet 5-HT
There was no significant difference in fasting 5-HT
(PRP) levels between patients and recovered controls
(P = 0.3). The PI-IBS ⁄FD patients had a significantly
lower plasma 5-HIAA compared with controls at all
time points )30 (P = 0.05), 0 min (P = 0.04), 210 min
(P = 0.04) and 240 min (P = 0.01) and a reduced AUC
0–240 min (Table 2). We found no correlation between
symptom scores and 5-HIAA, neither fasting nor
postprandially.
Table 1. Dyspepsia score during the 557 kcal carbohy-
drate rich meal in patients with Giardia-induced PI-
IBS ⁄ FD and recovered controls. Data are expressed as








(n = 18) P value
Abdominal pain 45 (0–218) 0 (0–15) 0.005
Nausea 150 (38–255) 0 (0–8) 0.0001
Bloating 390 (248–525) 30 (0–60) 0.0001
Fullness 248 (120–420) 30 (0–135) 0.0001
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Plasma cholecystokinin
Figure 2 shows the average plasma CCK levels during
the test meal. We found no significant differences at
individual time points (ANOVA) between groups. The
area under curve (AUC) of CCK tended to be higher in
the PI-IBS ⁄FD group compared with recovered con-
trols, but this did not reach statistical significance
(P = 0.07). In the PI-IBS ⁄FD group, plasma CCK
showed a weak, but significant positive correlation to
fullness score at 60 min (P = 0.025, r = 0.3), at
120 min (P = 0.04, r = 0.2), at 180 min (P = 0.004,
r = 0.4) and at this time also to bloating scores
(P = 0.004, r = 0.2).
Duodenal histology
We found mild duodenitis in one PI-IBS ⁄FD patient,
while others had a normal macroscopic appearance. Five
patients had mild chronic inflammation in routine his-
tological analysis of duodenal mucosa. One subject from
the recovered controls had mild oesophagitis visible
endoscopically, while three other subjects had signs of
microscopic duodenitis with mild chronic inflammation.
Duodenal 5-HT content, 5-HIAA, ratio 5-HIAA ⁄
5-HT
There was no significant difference of the content of
5-HT (nmol ⁄mg) duodenal tissue between the Giardia
PI-IBS ⁄FD patients (mean 21.1  4.1) compared to
controls (mean 16.8  4.0, P < 0.45) (Table 3). The
5-HIAA tended to be lower in the patients (mean
18.6  3.5 nmol ⁄mg) compared with controls (mean
25.4  3.7), but this difference did not reach a signifi-
cant level (P = 0.13). However, patients had signifi-
cantly lower 5-HIAA ⁄5-HT ratio (1.58  0.4) than
controls (5.02  1.6) (P = 0.05).
5-HT- and CCK-containing EC cells,
chromogranin A and mast cells
The main finding of our study was that 6 months or
more after Giardia infection, the 5-HT-containing EC
cell count was significantly reduced in the PI-IBS ⁄FD
patients (mean 27.04  5.8 cells ⁄mm2) compared with
the recovered controls (60.8  11.9), P < 0.009
(Figure 3). There was a weak, but significant, positive
Table 2. Fasting and postprandial plasma 5-HT and 5-
HIAA concentrations during the 557 kcal carbohydrate-
rich meal in Giardia-induced PI-IBS ⁄ FD patients and









5-HT (PRP) nmol ⁄ 109 platelets
)90 min 3.3 (3.2–3.9) 3.7 (2.7–4.6) 0.3
5-HIAA (PPP) nmol ⁄ L
)30 min 14.9 (13.1–16.8) 17.3 (14.4–20.4) 0.04
0 min 15.1 (12.3–17.9) 18.1 (14.0–21.9) 0.03
210 min 12.0 (10.2–14.2) 14.1 (12.6–17.3) 0.05
240 min 11.8 (10.4–14.9) 15.4 (13.6–18.2) 0. 03
AUC for
5-HIAA (PPP)
3718 (2884–4260) 4386 (3625–4933) 0.03
Table 3. Comparison of the duodenal mucosal content of
5-HT, 5-HIAA and 5-HIAA ⁄ 5-HT ratio from patients with
Giardia-induced PI-IBS ⁄ FD and recovered controls. Data






(n = 19) P value
5-HT (pmol ⁄mg) 21.1  4.1 16.8  4.0 0.45
5-HIAA (pmol ⁄mg) 18.6  3.5 25.4  3.7 0.2


























–30.0 30.0 60.0 90.0
Time (min)
120.0 150.0 180.0 210.0 240.0
0.0
0.0
Figure 2. The effect of 557 kcal carbohydrate-rich test
meal on plasma CCK levels in Giardia-induced PI-IBS ⁄ FD
(n = 20) and recovered controls (n = 18) (P = 0.07). Data
are shown as mean  S.E.M.
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correlation between EC-cell numbers and mucosal
5-HT content (linear regression r2 = 0.2, P = 0.05).
However, enteroendocrine cells containing CCK were
more numerous in patients with PI-IBS ⁄FD compared
with controls (P = 0.02) (Figure 4). Furthermore, the
ratio of CCK ⁄5-HT cells was significantly greater in
PI-IBS ⁄FD (P < 0.002) (Table 4).
There were no significant differences in the chro-
mogranin A containing cell counts (P = 0.4) or mast
cell counts (P = 0.8) between the groups.
DISCUSSION
Most previous studies of post-infectious functional
gastrointestinal diseases (PI-FGIDs) have focused on
bacterial causes of gastroenteritis, which are character-
ized by inflammation and mucosal tissue destruction.
However, more recently, PI-FGIDs have been described
also after Trichinella infection9 and viral gastroenteri-
tis3, 24 indicating that there are multiple mechanisms
underlying the post-infectious response. Giardia lamblia
is a common protozoan cause of gut infections,
especially in the developing world. Disease severity
may differ from asymptomatic to a severe clinical pic-
ture with diarrhoea, nausea, abdominal pain and mal-
absorption. The Giardia parasite resides in the lumen
and attaches to the epithelium, but does not invade
the mucosa. No toxin has been found, and only occa-
sionally does it cause mucosal inflammatory reactions
or villous shortening.25 Factors in both microbe and
host are thought to play a role in the variation seen in
the clinical and histological picture, and a surprisingly
high frequency of mucosal inflammation and pro-
longed symptoms was observed in a subset of patients
after the Bergen outbreak.10 Many of these went on to
develop post-infectious functional gastrointestinal dis-
eases, while the initially inflamed duodenal mucosa
normalized.26 In the present study, where duodenal
biopsies were taken 6 months or longer after clearance
of the Giardia infection, we also found few duodenal
inflammatory changes.
EC-cell counts and 5-HT levels
Our study shows that patients with persisting abdomi-
nal symptoms after Giardia infection have lower num-
ber of 5-HT containing enterochromaffin (EC) cells in
duodenal mucosa as well as lower plasma 5-HT mea-
sured as 5-HIAA during a meal. To our knowledge,
this is the first report concerning mucosal and plasma
5-HT changes in patients with Giardia-induced PI-
IBS ⁄FD. The decrease in EC cells of about 50% was
striking and unexpected. CgA positive cells did not


















Figure 4. Duodenal CCK containing EC cell count ⁄mm2
(mean  S.E.M., P = 0.02) in Giardia-induced PI-IBS ⁄ FD
patients (n = 28) and recovered controls (n = 19).
Table 4. Duodenal histology analysis in patients with
Giardia-induced PI-IBS ⁄ FD and recovered controls. Data







(n = 19) P value
5-HT producing EC
cells count ⁄mm2
27.04  5.8 60.8  11.9 0.009
CCK producing EC
cells count ⁄mm2
64.9  5.5 43.8  5.4 0.02
CCK ⁄ 5-HT ratio 17.45  5.85 5.36  4.0 0. 002
Mast cells ⁄mm2 13.1  0.8 12.6  1.2 0.8















Figure 3. Duodenal 5-HT containing EC cell count ⁄mm2
(mean  S.E.M., P = 0.009) in Giardia-induced PI-IBS ⁄ FD
patients (n = 28) and recovered controls (n = 19).
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numbers were unaltered. Previous studies of PI-IBS
after bacterial enteritis have shown greater 5-HT con-
taining EC cell counts and increased 5-HT content in
human rectal mucosa.2, 15, 27, 28 In the present study,
we did not assess colonic 5-HT and so cannot exclude
the possibility that duodenal and colonic responses
might be different.
Studies in mice suggested that while Trichinella spi-
ralis infection caused an inflammatory response in the
jejunum with an increase in enterochromaffin cells, in
the colon, there was a decrease.9 It is possible that the
differing immune responses in different regions of the
gut can drive enteroendocrine cell numbers both up
and down as they have receptors for cytokines on their
surface.7 Similar contrasting changes can be seen in
the antral mucosa with H. pylori infection, which
causes an increase in gastrin-containing cells, while
somatostatin cell numbers decrease.8
We also found the duodenal mucosa 5-HT turn-
over, as assessed by 5-HIAA ⁄5-HT ratio, to be
decreased, a feature we previously reported in both
PI-IBS and IBS with constipation.15 As mucosal
biopsy 5-HIAA is derived only from metabolism of
5-HT secreted by enterochromaffin cells after uptake
by the serotonin transporter (SERT), a reduced 5-
HIAA ⁄5-HT ratio implies either impaired release of 5-
HT or impaired SERT function. Previous studies do
suggest that inflammation depresses SERT levels; an
effect again likely to be mediated by local cyto-
kines,29 but in the current study, impaired release
could also play a part.
Cholecystokinin and symptoms
Contrasting our 5HT-findings, duodenal mucosal CCK-
containing cells were increased and postprandial
plasma CCK tended to increase. Elevated CCK levels
have previously been reported both in a pilot study in
humans with acute symptomatic giardiasis11 and in a
mouse model with acute giardiasis.30 Furthermore,
previous studies have shown an exaggerated and pro-
longed postprandial CCK release in IBS patients.31, 32
Excess of CCK in some IBS patients might explain the
benefit of CCK antagonist, dexloxiglumide33 in IBS,
which has also been shown to accelerate gastric emp-
tying in female patients with IBS34 and also to block
the exaggerated postprandial colonic contractions in
IBS patients in response to CCK infusions.35
Although the increase in plasma CCK in PI-IBS ⁄FD
patients was not significant, it should be noted that a
local increase could still stimulate vagal afferents in a
paracrine fashion. Therefore, we cannot exclude the
idea that increased CCK release might be responsible
for symptoms. However, definite conclusion on this
point will require a randomized placebo-controlled
trial of a specific CCK antagonist.
We found that CCK levels in the PI-IBS ⁄FD group
were correlated with postprandial fullness, which is an
important symptom in functional dyspepsia. Many
other studies have suggested that CCK has a major
influence on satiety,36 being released mainly by die-
tary fat and acting both on vagal afferents37 as well as
the brainstem. The correlation observed between
increased release of CCK and a sense of fullness might
be mediated by the delay in gastric emptying that we
have observed in patients with persistent symptoms
following Giardia infection38 and which CCK infusions
are known to cause.39
Although we based our power calculation on a pre-
vious study,11 we found smaller differences, possibly
because our study was performed many months after
the initial infection. While we found a numerically
higher plasma CCK before and after a carbohydrate
rich meal in PI-IBS ⁄FD compared with asymptomatic
controls, this failed to reach a statistical significance
probably because our study was underpowered.
In summary, we found that patients with long-last-
ing abdominal symptoms 6 months or more after
Giardia infection had lower plasma 5-HIAA after a
high caloric mixed meal and lower duodenal 5-HT
containing EC cells count than recovered controls.
Moreover, they had an increased number of duodenal
CCK cells and plasma CCK was associated with dys-
peptic symptoms. This suggests that CCK could have
an important role in generating symptoms in patients
with Giardia-induced PI-IBS ⁄FD, while 5-HT seems
less important in this variety of post-infectious func-
tional gastrointestinal disease, a feature which may
explain why 5-HT3 antagonists show little benefit in
this condition.38
ACKNOWLEDGEMENTS
Declaration of personal interests: None. Declaration of
funding interests: Professor Spiller has received grant
support from GlaxoSmithKline and Novartis. The study
was funded by the Department of Medicine, Haukeland
University Hospital. For laboratory work, we thank
Elisabeth Tombra Halvorsen, Eva Elisabeth Fosse and
Turid Olsen.
890 V . D IZDAR et al.
Aliment Pharmacol Ther 31, 883–891
ª 2010 Blackwell Publishing Ltd
REFERENCES
1 Gwee KA, Leong YL, Graham C, et al. The
role of psychological and biological fac-
tors in postinfective gut dysfunction. Gut
1999; 44: 400–6.
2 Spiller RC, Jenkins D, Thornley JP, et al.
Increased rectal mucosal enteroendocrine
cells, T lymphocytes, and increased gut per-
meability following acute Campylobacter
enteritis and in post-dysenteric irritable
bowel syndrome.Gut 2000; 47: 804–11.
3 Tack J, Demedts I, Dehondt G, et al. Clini-
cal and pathophysiological characteristics
of acute-onset functional dyspepsia. Gas-
troenterology 2002; 122: 1738–47.
4 Mearin F, Perez-Oliveras M, Perello A, et al.
Dyspepsia and irritable bowel syndrome
after a Salmonella gastroenteritis outbreak:
one-year follow-up cohort study.Gastroen-
terology 2005; 129: 98–104.
5 Barbara G, Vallance BA, Collins SM. Persis-
tent intestinal neuromuscular dysfunction
after acute nematode infection in mice.
Gastroenterology 1997; 113: 1224–32.
6 Sigurdsson L, Flores A, Putnam PE, Hy-
man PE, Di Lorenzo C. Postviral gastropa-
resis: presentation, treatment, and
outcome. J Pediatr 1997; 131: 751–4.
7 Wang H, Steeds J, Motomura Y, et al.
CD4 + T cell-mediated immunological
control of enterochromaffin cell hyperpla-
sia and 5-hydroxytryptamine production in
enteric infection.Gut 2007; 56: 949–57.
8 Sumii M, Sumii K, Tari A, et al. Expression
of antral gastrin and somatostatin mRNA
in Helicobacter pylori-infected subjects.
Am J Gastroenterol 1994; 89: 1515–9.
9 Wheatcroft J, Wakelin D, Smith A, et al.
Enterochromaffin cell hyperplasia and de-
creased serotonin transporter in a mouse
model of postinfectious bowel dysfunction.
NeurogastroenterolMotil 2005; 17: 863–70.
10 Hanevik K, Hausken T, Morken MH, et al.
Persisting symptoms and duodenal
inflammation related to Giardia duode-
nalis infection. J Infect 2007; 55: 524–30.
11 Leslie FC, Thompson DG, McLaughlin JT,
et al. Plasma cholecystokinin concentra-
tions are elevated in acute upper gastroin-
testinal infections. QJM 2003; 96: 870–1.
12 Thompson WG, Longstreth GF, Drossman
DA, et al. Functional bowel disorders and
functional abdominal pain. Gut 1999;
45(Suppl 2): II43–7.
13 Talley NJ, Stanghellini V, Heading RC,
et al. Functional gastroduodenal disor-
ders. Gut 1999; 45(Suppl 2): II37–42.
14 Houghton LA, Atkinson W, Whitaker RP,
Whorwell PJ, Rimmer MJ. Increased
platelet depleted plasma 5-hydroxytrypta-
mine concentration following meal inges-
tion in symptomatic female subjects with
diarrhoea predominant irritable bowel
syndrome. Gut 2003; 52: 663–70.
15 Dunlop SP, Coleman NS, Blackshaw E,
et al. Abnormalities of 5-hydroxytrypta-
mine metabolism in irritable bowel syn-
drome. Clin Gastroenterol Hepatol 2005;
3: 349–57.
16 Atkinson W, Lockhart SJ, Houghton LA,
Keevil BG. Validation of the measurement
of low concentrations of 5-hydroxytryp-
tamine in plasma using high performance
liquid chromatography. J Chromatogr B
Analyt Technol Biomed Life Sci 2006;
832: 173–6.
17 Ronnblom A, Danielsson A, El Salhy M.
Intestinal endocrine cells in myotonic
dystrophy: an immunocytochemical and
computed image analytical study. J Intern
Med 1999; 245: 91–7.
18 Friend DS, Gurish MF, Austen KF, Hunt J,
Stevens RL. Senescent jejunal mast cells
and eosinophils in the mouse preferen-
tially translocate to the spleen and drain-
ing lymph node, respectively, during the
recovery phase of helminth infection. J
Immunol 2000; 165: 344–52.
19 Sjolund K, Sanden G, Hakanson R, Sun-
dler F. Endocrine cells in human intes-
tine: an immunocytochemical study.
Gastroenterology 1983; 85: 1120–30.
20 Sandstrom O, El Salhy M. Ageing and
endocrine cells of human duodenum.
Mech Ageing Dev 1999; 108: 39–48.
21 Zigmond AS, Snaith RP. The hospital
anxiety and depression scale. Acta Psy-
chiatr Scand 1983; 67: 361–70.
22 Eysenck SB, Eysenck HJ, Barret P. A
revised version of the psychoticism scale.
Person Individ Diff 1985; 6: 21–9.
23 Talley NJ, Verlinden M, Jones M. Quality of
life in functional dyspepsia: responsiveness
of the Nepean Dyspepsia Index and devel-
opment of a new 10-item short form. Ali-
ment Pharmacol Ther 2001; 15: 207–16.
24 Marshall JK, Thabane M, Borgaonkar MR,
James C. Postinfectious irritable bowel
syndrome after a food-borne outbreak of
acute gastroenteritis attributed to a viral
pathogen. Clin Gastroenterol Hepatol
2007; 5: 457–60.
25 Oberhuber G, Kastner N, Stolte M. Giardi-
asis: a histologic analysis of 567 cases.
Scand J Gastroenterol 1997; 32: 48–51.
26 Hanevik K, Dizdar V, Langeland N, Haus-
ken T. Development of functional gastro-
intestinal disorders after Giardia lamblia
infection. BMC Gastroenterol 2009; 9: 27.
27 Dunlop SP, Jenkins D, Neal KR, Spiller
RC. Relative importance of enterochro-
maffin cell hyperplasia, anxiety, and
depression in postinfectious IBS. Gastro-
enterology 2003; 125: 1651–9.
28 Dunlop SP, Jenkins D, Spiller RC. Distinc-
tive clinical, psychological, and histologi-
cal features of postinfective irritable
bowel syndrome. Am J Gastroenterol
2003; 98: 1578–83.
29 Foley KF, Pantano C, Ciolino A, Mawe GM.
IFN-gamma and TNF-alpha decrease sero-
tonin transporter function and expression
in Caco2 cells. Am J Physiol Gastrointest
Liver Physiol 2007; 292: G779–84.
30 Li E, Zhao A, Shea-Donohue T, Singer SM.
Mast cell-mediated changes in smooth
muscle contractility during mouse giardia-
sis. Infect Immun 2007; 75: 4514–8.
31 Sjolund K, Ekman R, Lindgren S, Rehfeld
JF. Disturbed motilin and cholecystokinin
release in the irritable bowel syndrome.
Scand J Gastroenterol 1996; 31: 1110–4.
32 Zhang H, Yan Y, Shi R, et al. Correlation
of gut hormones with irritable bowel syn-
drome. Digestion 2008; 78: 72–6.
33 Cann PA, Rovati LC, Smart HL, Spiller
RC, Whorwell PJ. Loxiglumide, a CCK-A
antagonist, in irritable bowel syndrome. A
pilot multicenter clinical study. Ann N Y
Acad Sci 1994; 713: 449–50.
34 Cremonini F, Camilleri M, McKinzie S,
et al. Effect of CCK-1 antagonist, dexloxi-
glumide, in female patients with irritable
bowel syndrome: a pharmacodynamic
and pharmacogenomic study. Am J Gas-
troenterol 2005; 100: 652–63.
35 Chey WY, Jin HO, Lee MH, Sun SW, Lee
KY. Colonic motility abnormality in
patients with irritable bowel syndrome
exhibiting abdominal pain and diarrhea.
Am J Gastroenterol 2001; 96: 1499–506.
36 Moran TH. Cholecystokinin and satiety:
current perspectives. Nutrition 2000; 16:
858–65.
37 Blackshaw LA, Grundy D. Effects of
cholecystokinin (CCK-8) on two classes
of gastroduodenal vagal afferent fibre.
J Auton Nerv Syst 1990; 31: 191–201.
38 Dizdar V, Gilja OH, Hausken T. Increased
visceral sensitivity in Giardia-induced
postinfectious irritable bowel syndrome
and functional dyspepsia. Effect of the
5HT3-antagonist ondansetron. Neurogas-
troenterol Motil 2007; 19: 977–82.
39 Cote F, Pare P, Friede J. Physiological
effect of cholecystokinin on gastric
emptying of liquid in functional dyspep-
sia. Am J Gastroenterol 1995; 90:
2006–9.
EC CELLS , 5-HT AND CCK IN GIARDIA IBS AND FUNCTIONAL DYSPEPSIA 891
Aliment Pharmacol Ther 31, 883–891
ª 2010 Blackwell Publishing Ltd
Duodenal Lymphocytes in Giardiasis • JID 2019:220 (15 July) • 321
The Journal of Infectious Diseases
Prolonged Duodenal Mucosal Lymphocyte Alterations 
in Patients With and Without Postinfectious Functional 
Gastrointestinal Disorders After Giardia Infection
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Background. Persisting low-grade inflammation is suggested to play a role in postinfectious functional gastrointestinal disor-
ders (PI-FGIDs). The present study examined alterations in duodenal mucosal lymphocytes during and after Giardia gastroenteritis 
in patients who did, or did not, develop PI-FGIDs.
Methods. Duodenal mucosal intraepithelial lymphocytes (IELs) and lamina propria CD3, CD4, CD8, and CD20 lymphocytes 
were quantified in 28 patients with chronic giardiasis (CG), 66 patients with persistent abdominal symptoms after acute Giardia 
infection (PI-FGID), 19 recovered controls (RCs), and 16 healthy volunteers (HCs). Associations with illness duration, abdominal 
symptoms, and histology grade were assessed.
Results. Duodenal CD4 IELs were significantly elevated in CG, then decreased, followed by an upward trend after 1 year in both 
the PI-FGID and RC groups. Duodenal lamina propria crypt CD4 T cells were decreased in CG, and stayed low for about 14 months 
before normalizing in both the PI-FGID and RC groups. Lamina propria CD20 cells were persistently elevated in all 3 Giardia-
exposed groups. Biopsies with microscopic inflammation showed increased lamina propria CD20 levels.
Conclusions. Duodenal mucosal lymphocyte alterations were prolonged after Giardia infection, but similar in patients who 
developed PI-FGID and recovered asymptomatic controls.
Keywords. duodenal mucosa; Giardia; functional gastrointestinal disorders; PI-IBS; histology; B cell.
 
Giardia lamblia (synonyms duodenalis, intestinalis) is an intes-
tinal protozoan parasite that infects the small intestine causing 
giardiasis, resulting in a variable spectrum of abdominal symp-
toms. It often causes a gastroenteritis with prolonged diarrheal 
illness and abdominal cramping, but may also be asymptomatic. 
It is commonly seen in returning travelers from low-resource 
settings and a frequent cause of waterborne outbreaks.
Giardiasis has been recognized as a risk for developing post-
infectious functional gastrointestinal disorders (PI-FGIDs) 
[1–4]. Irritable bowel syndrome (IBS) is the most common of these 
conditions and occurs in 3%–36% of individuals after infectious 
gastroenteritis [5, 6]. Follow-up studies of laboratory-confirmed 
Giardia infection after an outbreak in Bergen, Norway, found a 
high prevalence of IBS after 3, 6, and 10 years [4, 7, 8].
The mechanisms behind development of FGID are not 
known, but are regarded to be multifactorial. Several studies 
suggest that persisting low-grade inflammation, with increased 
numbers of mucosal B and T lymphocytes, could be an impor-
tant contributing factor [6, 9, 10].
Giardia infection is known to elicit both B- and T-cell–de-
pendent immune responses [11–13]. Animal studies have 
shown that microvillous injury, disaccharidase deficiencies, and 
increased crypt/villus ratio are mediated by CD8 cells, while 
CD4 cells contribute to parasite clearance [14]. Mucosal lym-
phocyte kinetics during and after giardiasis, and their poten-
tial association with development of PI-FGID, have not been 
examined before.
The aim of the present study was to evaluate lymphocyte 
alterations in the duodenal mucosa in giardiasis and to examine 
whether such alterations were associated with persisting ab-
dominal symptoms following Giardia infection.
MATERIALS AND METHODS
Study Subjects
This study is based on the clinical and research data and spec-
imens obtained during a structured workup and follow-up of 
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patients referred to Haukeland University Hospital in Bergen, 
Norway [15]. Patients were referred due to persisting abdominal 
symptoms after the Giardia outbreak in Bergen in 2004. They 
were examined and biopsied between January 2005 and April 
2006 (Figure 1), at which time they all had been ill for 3 months 
or more. Biopsies were available from 28 patients with chronic 
giardiasis (CG) and from 72 patients (66 of these randomly 
selected for this study) in whom Giardia had been successfully 
eradicated (diagnosed by at least 3 microscopy-negative sam-
ples and later verified with negative polymerase chain reaction). 
A  detailed workup including upper endoscopy with duodenal 
biopsies, serum antiendomysial antibodies, antitissue transgluta-
minase antibodies, routine blood screening tests, immunoglob-
ulins, immunoglobulin E, and fecal calprotectin did not reveal 
other organic disease in the Giardia-negative patients, who were 
diagnosed as having PI-FGID. To evaluate possible coinfection, 
Helicobacter pylori was analyzed in frozen stool samples by stool 
antigen test [16] in 20 randomly selected PI-FGID patients.
Control Groups
Nineteen patients with laboratory-confirmed giardiasis during 
the outbreak, who had recovered well after treatment, were 
selected randomly and recruited by invitation letter/telephone 
and examined 12–19 months after onset of the gastroenteritis 
[17]. These patients were designated the recovered control (RC) 
group. Additionally, 16 healthy controls (HCs), with no history 
of persisting bowel symptoms and not taking immunosuppres-
sive medication, were recruited by advertisements and went 
through the same investigations as the cases (Figure 1).
All participants provided written informed consent and the 
study was approved by the Regional Committees for Medical 
and Health Research Ethics (REC WEST, Norway) number 
2016/1632.
Symptoms
Abdominal symptom scores for the last 30 days were recorded 
on the day biopsies were taken. Nausea, bloating, abdominal 
pain, diarrhea, and constipation were scored using an ordinal 
scale from 0 (no symptoms) to 10 (severe symptoms) [18]. 
Illness duration was defined as the time from the start of acute 
symptoms of Giardia infection until the date of clinical exam-
ination with biopsies. At follow-up, PI-FGID patients were 
asked to complete a validated Norwegian version of the ROME 
II questionnaire [19].
Duodenal Biopsies and Histology
From all study groups, 3 biopsy specimens were obtained from 
the second part of the duodenum, embedded in paraffin, and 
processed for routine hematoxylin and eosin staining and 
immunohistochemistry. In 11 of the PI-FGID patients exam-
ined at 16–19 months of illness duration, biopsies were available 
from a previous examination 3–7 months after onset of symp-
toms, when 8 were still Giardia positive and 3 were Giardia 
negative.
The severity of duodenal inflammation, as well as the archi-
tecture of villi and crypts, was determined by an experienced 
pathologist in a blinded manner. The routine histological find-
ings were classified as H0 if they were normal and as H1 if there 
was inflammation with infiltration of leukocytes and increased 
number of plasma cells in the lamina propria with or with-
out shortening and blunting of intestinal villi (Supplementary 
Figures 1–3).
Giardiasis outbreak in 2004 in Bergen, Norway
1252 laboratory-confirmed giardiasis cases
Patients referred with persistent abdominal
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Figure 1. Flowchart of the study population and study design. Abbreviations: PCR, polymerase chain reaction; PI-FGID, postinfectious functional gastrointestinal disorder.
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Immunohistochemistry
Formalin-fixed, paraffin-embedded duodenal specimens were 
cut into 4-µm sections, de-paraffinized in xylene, and rehy-
drated through graded ethanol series and distilled water.
After heat-induced epitope retrieval in Tris–ethylenedi-
aminetetraacetic acid buffer, pH 9.0 for 15 minutes at 350 W, 
endogen peroxidase activity was blocked with 0.3% peroxide 
(Dako) for 5 minutes. Tissue was then incubated with primary 
antibodies: CD3 (polyclonal rabbit antihuman CD3, 1/400, 
Dako), CD4 (monoclonal antibody NCL-CD4-IF6, clone 
IF6, 1/25), CD8 (monoclonal mouse antihuman CD8α, clone 
C8/144B, 1/100, Dako), and CD20 (monoclonal mouse antihu-
man CD20, clone L26, 1/1000, Dako).
We used EnVision (Dako 5007) secondary antibody for 30 min-
utes, with 3,3’-diaminobenzidine as chromogen. Sections were 
counterstained with hematoxylin (Dako S3301) (Supplementary 
Figures 4 and 5).
Methods of Cell Counting
Lymphocyte subsets were counted in 3 anatomically defined 
regions. The numbers of intraepithelial lymphocytes (IELs) 
located above the basal membrane, per 100 epithelial cells, 
were counted on 5 well-orientated villi with longitudinal sec-
tions and expressed as the number of IELs per 100 epithelial 
cells [20].
Lamina propria villous (Lpv) lymphocytes located under-
neath epithelial basal membrane were assessed in 5 villi with 
results expressed as average cell counts per area (cells/mm2). 
Lamina propria crypt (Lpc) lymphocytes were counted per area 
within 5 consecutive, nonoverlapping ×200 fields of Lpc and the 
results averaged (cell count/mm2).
Positive cells in vicinity of lymphoid follicles or clusters were 
not taken into consideration. Only cells with a visible nucleus 
were considered as positive and counted.
The cell counts were performed using Olympus pro-
gram Cell P image analysis software, with a ×200 objective. 
All measurements were performed in a blinded manner 
by V.  D.  and double-checked by a pathologist (O. D.  L.). 
Interobserver agreement (V. D. and O. D. L.) and intraobserver 
agreement (V. D.) for counting of CD cells was assessed using 
Bland–Altmann correlations test.
We also analyzed correlation between T- and B-cell data 
obtained in this study with duodenal enterochromaffin (EC) 
cell numbers from 19 patients in the PI-FGID group and 19 
RCs, which were available from a previous study [21].
Statistical Analysis
Age and illness duration are expressed as median (range). 
Abdominal symptom score and lymphocyte cell counts are 
presented as median  (interquartile range [IQR]). Differences 
between groups for age, illness duration, and CD cell counts 
were assessed using the Kruskal–Wallis test. The Fisher’s exact 
test was used for categorical values. Mann–Whitney unpaired 
test was used for comparisons of histology and lymphocyte 
counts. The Wilcoxon paired test was used to compare lympho-
cyte counts in repeated biopsies. Correlation analyses were per-
formed using the Pearson (parametric data) or Spearman rank 
test (nonparametric data). All data were analyzed using Graph 
Pad Prism 4 software. Due to multiple comparisons across 4 
groups and 11 locations of lymphocyte subsets, we set an arbi-
trary P value of <.01 as the level of significance.
RESULTS
As shown in Table 1, there was no significant difference in age 
or sex between study groups. No correlation was found between 
participant age or sex and T- and B-cell subsets, except that 
PI-FGID females had higher levels of CD3 IELs (16 [13–23] 
vs 11 [8–19]; P = .002) and lower Lpc CD8 (245 [182–349] vs 










Age, y, median (range) 27 (19–48) 28 (18–51) 29 (22–45) 36 (22–56) NSa
Female sex, No. (%) 17 (61) 40 (61) 9 (48) 11 (69)
Time since onset of giardiasis, mo, median (range) 6 (3–14) 10 (3–19) 15 (12–19) NA < .0001a
Duodenal inflammation, No. (%)
 Macroscopic 5 (17.9) 4 (6.1) 0 0 .05b
 Microscopic 24 (85.7) 19 (28.8) 3 (15.8) 0 < .0001b
Symptom score (n = 22) (n = 50) (n = 19) (n = 16)
 Abdominal pain/discomfort 8 (5–8) 5 (3–8) 0 (0–2) 0 < .0001a
 Nausea 7 (3–8) 3 (1–6) 0 (0–1) 0 < .0001a
 Bloating 8 (5–9) 7 (4–8) 2 (0–4) 1 (0–2) < .0001a
 Diarrhea 8 (5–10) 6 (3–8) 0 (0–1) 0 < .0001a
 Constipation 1 (0–3) 1 (0–4) 0 (0–1) 1 (0–1) .03a
Symptom data are shown as median (interquartile range).
Abbreviations: NA, not applicable; NS, not significant; PI-FGID, postinfectious functional gastrointestinal disorder.
aKruskal–Wallis test across 4 groups.
bFisher’s exact test.
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328 [282–425]; P = .001). However, there were no differences in 
CD3 IEL levels between the 4 study groups.
Microscopic inflammation was seen in a high proportion of 
patients with CG (85.7%), some of the patients with PI-FGID 
(28.8%), and a few of the RCs, but not among HCs (Table 1). 
Twenty PI-FGID patients tested for H. pylori were all negative.
Abdominal Symptoms
There were significant differences in abdominal symptoms 
between the groups (Table  1). Abdominal pain and discom-
fort, diarrhea, and bloating were the most common symptoms 
in the patients with CG and PI-FGID. Only diarrhea found to 
have a significantly higher score among CG cases compared to 
PI-FGID (P = .009). There were few symptoms among recovered 
and healthy controls. Females scored significantly higher than 
males for nausea (P < .0001) and abdominal pain (P = .005) in 
all 3 Giardia-exposed groups.
Of 66 PI-FGID patients, 42 (64%) completed a ROME II 
form between October 2005 and April 2007, at median illness 
duration of 19  months (range, 12–34  months). Thirty-seven 
of 42 (56%) fulfilled criteria for IBS, 3 of 42 (5%) had func-
tional dyspepsia (FD), 5 of 42 (8%) had both FD and IBS, and 
2 patients (3%) had functional abdominal bloating. Subtyping 
of the 37 PI-IBS patients revealed 54% IBS-A, 35% IBS-D, and 
11% IBS-C.
Correlation Between T and B Cells and Illness Duration
In the preliminary analysis of lymphocyte subsets, we saw 
gradual changes over time in the PI-FGID and RC groups. In 
the PI-FGID group, illness duration was positively correlated 
with Lpc CD4 cells (P = .0005, Spearman r = 0.4) and with Lpc 
CD8 cells (P = .005, Spearman r = 0.3). Illness duration in RC 
correlated positively with Lpv CD4 cells (P = .005, r = 0.6), and 
Lpc CD4 cells (P  =  .0002, r  =  0.8). We therefore divided the 
PI-FGID and RC groups into subgroups of 4-month intervals 
with regard to onset of symptoms.
In patients with chronic giardiasis, we found a significant 
correlation between illness duration and a small gradual in-
crease in Lpc CD8 cells (P = .005, Spearman r = 0.5). The CD3, 
CD4, or B-cell populations were not altered over time in CG.
Macroscopic and Microscopic Inflammation
Macroscopic duodenitis was not common in the participants 
(Table 1). Enough patients were available in the PI-FGID group 
with illness duration 3–10 months to assess duodenal inflam-
mation grade and lymphocyte populations. Histologically 
normal duodenal biopsies in PI-FGID  had lower CD20 cell 
counts in both villus (0 [0–5] vs 25 [5–43]; P = .0001) and crypt 
(16 [12–26] vs 37 [25–42]; P =  .0002) than those with micro-
scopic inflammation (Figure 2).
The same trend was seen in the PI-FGID patients with ill-
ness duration 11–19  months, in RCs, and in the CG group 
(Supplementary Table 2). No significant differences in CD4 and 
CD8 cell counts between histologically normal and inflamed 
biopsies were found.
Intraepithelial Lymphocytes
When compared to healthy controls, there were no significant 
differences in CD8 IELs between the 3 Giardia-exposed groups 
(Supplementary Table 1). However, CD4 IELs were significantly 
increased in chronic giardiasis compared to healthy controls, 
as shown in Figure 3. Somewhat surprisingly, there was a dip 
toward normal levels in the PI-FGID group at 7–10 months of 
illness duration, with a later increase. The same development 
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Figure 2. Duodenal lamina propria villus and lamina propria crypt CD20 cells in biopsies with normal histology (H0) and histological inflammation (H1) in patients with 
chronic giardiasis, those with PI-FGID, recovered controls, and healthy controls. Values above horizontal whiskers are P values for comparisons between groups.
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Using 30 IELs per 100 epithelial cells as an upper limit of 
normal, CD3 IELs were found to be elevated in only 1 patient 
with chronic giardiasis, 2 with PI-FGID, and 2 HC subjects.
Lamina Propria T Cells
In patients with chronic giardiasis, the number of Lpc 
CD4 T cells was significantly lower (181 [144–226]) com-
pared to HCs (323 [250–376]) (P < .0001) (Figure  4 and 
Supplementary Table  2). PI-FGID patients with recent 
Giardia infection had low levels of Lpc CD4 cells, similar 
to CG, but a gradual increase was observed in patients as 
illness lasted ≥11 months. At 15–19 months it reached the 
same level as HCs and was significantly increased compared 
to previous months.
The same pattern was observed in RCs where Lpc CD4 cells at 
12–14 months of illness duration were significantly lower compared 
to HCs (P = .0004), but rose to normal levels from 12–14 months to 
15–19 months (190 [138–216] vs 321 [254–405]; P = .0009).
Lpv CD4 T cells showed were very variable in CG, but 
decreased after eradication of the parasite, and then gradually 
increased in both PI-FGID and RC groups (Supplementary 
Table 1).
We did not observe any significant differences between the 4 
study groups regarding CD8 cells in crypts or villus.
Duodenal Lamina Propria B Cells
All 3 Giardia-exposed groups had significantly higher number 
of CD20 B cells in Lpv and Lpc lymphocytes compared with 
healthy controls (Figure 5).
The CD20 cell counts in the PI-FGID group was lower than 
in CG, decreased somewhat over time, and became more sim-
ilar to HC levels. Recovered controls had significantly higher 
levels of levels of CD20 B cells in both villus and crypt lympho-
cytes compared to HCs.
Repeated Duodenal Biopsies
In paired samples from the same patient from 2 time points, 
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Figure 3. Duodenal CD4 intraepithelial lymphocytes (IELs) in patients with chronic giardiasis (CG), those with postinfectious functional gastrointestinal disorder (PI-FGID), 




























































Figure  4. Duodenal  lamina propria crypt lymphocytes in patients with chronic 
giardiasis (CG), those with postinfectious functional gastrointestinal disorder 
(PI-FGID), recovered controls (RC), and healthy controls (HC). Values above horizon-
tal whiskers are P values for comparisons between groups.
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[118–193] to 227 [199–371]; P = .01) and CD8 cells (from 219 
[118–271] to 389 [275–434]; P = .01) (Figure 6).
Otherwise, there were no significant differences in duodenal 
intraepithelial or lamina propria cell counts for CD3, CD4, 
CD8, or CD20 lymphocytes in these 11 patients.
Correlation Between Duodenal EC Cells and T Cells
A previous study showed that EC cells were reduced in the 
PI-FGID group (n = 19) compared with the RC group (n = 19). 
When correlating lymphocyte data with available EC cell data 
(n  =  38), we found EC cells to positively correlate with CD4 
IELs (P =  .01, Spearman r = 0.4) and a tendency for correla-
tion with Lpc CD4 cells (P = .02, Spearman r = 0.4). Looking at 
the PI-FGID group only (n = 19), there was a positive correla-
tion between EC cell numbers and both Lpv CD4 cells (P = .01, 
Pearson r = 0.6) and Lpc CD4 cells (P = .008, Pearson r = 0.6).
DISCUSSION
In the present study, we identified alterations in duodenal mu-
cosal lymphocyte subsets during symptomatic chronic giar-
diasis, as well as prolonged differences in these subsets after 
successful treatment. Importantly, we did not observe impor-
tant differences in these major lymphocyte populations between 
patients who did and those who did not develop long-term 
PI-FGID symptoms. We found increased frequency of CD4 
IELs in chronic giardiasis that was sustained over time, espe-
cially in recovered asymptomatic patients, but also in patients 
with PI-FGID. In the lamina propria, CD4 T-cell numbers were 
high in the villus, but low in the crypt in chronic giardiasis. In 
both the PI-FGID and RC groups, lamina propria crypt CD4 
cells and CD8 cells gradually increased to normal levels >1 year 











































































































Figure 6. Duodenal lamina propria crypt CD4 cells, lamina propria crypt CD8 cells, and lamina propria villus CD20 cells in biopsy 1 (illness duration between 3 and 7 months) 
































































































Figure 5. Duodenal lamina propria villus and lamina propria crypt CD20 lymphocytes in patients with chronic giardiasis (CG), those with postinfectious functional gastroin-
testinal disorder (PI-FGID), recovered controls (RC), and healthy controls (HC). Values above horizontal whiskers are P values for comparisons between groups.
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controls, lamina propria CD20 cells were elevated during the 
whole follow-up period in all 3 Giardia-exposed groups.
To our knowledge, this is the first study describing duodenal 
mucosal intraepithelial and Lpv and Lpc lymphocyte kinetics 
over 1.5 years in patients with and without persistent abdom-
inal symptoms after gastroenteritis with a confirmed intestinal 
pathogen. A rigorous interpretation of the data was possible due 
to inclusion of groups with prolonged illness as well as recov-
ered controls exposed to the same pathogen.
Inflammation in Chronic Giardiasis
Previous studies of giardiasis have concluded that there were no 
specific histological changes in patients with symptomatic giar-
diasis except slightly increased CD3 IELs [22, 23]. Only rarely 
there are signs of inflammation and villous flattening [24].
In our study, only a few subjects had increased CD3 IEL 
counts >30. However, many of the Giardia positive cases (by 
stool examination) presented in this study had duodenal 
inflammation, but Giardia trophozoites could only be identified 
above the duodenal mucosa in 2 of 28 cases. It is known that 
some patients may present with a more profound inflammatory 
reaction to the Giardia infection such as this. Recently a similar 
set of 10 giardiasis cases was reported with inflamed, but par-
asite-free, duodenal mucosa, but uninflamed ileal mucosa with 
discernible trophozoites above it [25].
Intestinal T-Cell Alterations
Our results show that duodenal CD4 T cells can be decreased 
for many months after giardiasis. Most studies of intestinal lym-
phocytes after gastroenteritis have investigated colonic or rectal 
mucosa [9]. In patients with persistent abdominal symptoms 
after Campylobacter or Shigella infection, an increased count of 
EC cells and lamina propria T cells have been found in the large 
intestine when compared with HCs [26–28]. The only study of 
duodenal lymphocytes in PI-FGIDs patients is a small study of 
12 patients with PI-FD of unknown microbial etiology and 12 
patients with unspecified FD, and no HCs [29]. A reduced num-
ber of intravillar CD4 cells in PI-FD was found. Their conclu-
sion was that PI-FD patients showed an impaired ability of the 
immune system to terminate the inflammatory response after 
the acute insult. The long duration of recruitment into our study, 
and inclusion of a recovered control group exposed to the same 
infection, allows a better interpretation of the findings. As lower 
CD4 cell frequencies are present, and gradually increasing, in 
both the PI-FGID and RC groups, this finding seems to be a pro-
longed effect of the inflammatory response to the gastroenteritis, 
rather than associated with the presence of PI-FGID symptoms.
Interestingly, a recent mouse study found increased lev-
els of anti-inflammatory cytokine interleukin 10 (IL-10) to be 
important in controlling Giardia-induced T-cell responses both 
in the small and large intestine [30]; thus, the prolonged lower 
T-cell count observed in the present study could be induced via 
an IL-10–dependent pathway. That mouse study also revealed 
the possibility that individuals with Giardia-induced duode-
nal inflammation could also have some degree of concomitant 
colitis. Further research is needed to examine whether this may 
occur, and if it could trigger a longer-term dysfunction and 
development of FGID.
Duodenal Lamina Propria B Cells
Antibody-producing B cells have an important role in adaptive 
immune response and are important in clearing Giardia infec-
tion [11, 13]. All Giardia-exposed participants had elevated 
CD20 B-cell counts in both Lpv and Lpc compared to healthy 
controls. CD20 B cells in the lamina propria mainly represent 
resident local memory B cells, and not plasma cells as these 
are CD20 negative [31]. These cells are likely to be part of the 
acquired immune response against Giardia observed in epide-
miological studies [32].
There was a clear trend of gradual reduction over time of 
CD20 cells in the villi. However, in crypts, this trend was absent, 
and the increase was still present 15–19  months after initial 
infection. Separate counting of the 2 compartments avoided 
masking these differences.
Mucosal jejunal CD20 B cells have been found moder-
ately elevated in a Spanish study of patients with IBS-D com-
pared to healthy controls [10]. This cohort may have included 
PI-IBS patients, as IBS-D is a subtype commonly seen after 
gastroenteritis.
Surprisingly, there was a tendency for the RC group’s Lpv B cells 
not to normalize as well as in the PI-FGID group at 12–19 months. 
An explanation for this might be that 6 of these 19 RCs had mark-
edly elevated villus B cells compared to the rest of the group, indi-
cating potential intercurrent recent enteric infection.
Duodenal EC Cells
EC cells are dispersed throughout the gut and are the main 
source of serotonin (5-HT). It has been shown previously that 
secretory products from CD4 T cells interact with EC cells 
to enhance the production of 5-HT in the gut via Th2-based 
mechanisms [33]. Our previous finding of lower number of EC 
cells that is now found to be associated with a prolonged dip in 
CD4 cells in the PI-FGID group could indicate a temporarily 
lower 5-HT production after Giardia infection.
Limitations and Strengths
The main strength of this study is the relatively large number of 
patients in the CG and PI-FGID groups and the long inclusion 
time, allowing a description of the kinetics of mucosal lympho-
cyte populations. A  similar development in the 11 cases with 
repeated biopsies supported the finding in individual cases 
over time. The inclusion of Giardia-exposed RCs as well as HCs 
allowed results to be interpreted with more certainty.
There were some limitations of this study. We were not able 
to determine exactly when patients became Giardia negative 
after treatment, as many were referred after several courses of 
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metronidazole due to their prolonged symptoms. We also were not 
able to collect symptoms scores at the time of biopsy or ROME II 
follow-up forms from all patients in the CG and PI-FGID groups. 
Analysis of differences in lymphocyte counts according to histo-
logic inflammation suffered from a low number of cases except 
in the PI-FGID group with symptom duration of 3–10 months.
Conclusions
Chronic symptomatic Giardia infection is associated with ele-
vated CD4 IELs and with elevated B cells and decreased CD4 T 
cells in the duodenal lamina propria. In patients with PI-FGID 
symptoms after giardiasis and in RCs the same pattern was 
seen for more than a year before CD4 T cells were normaliz-
ing to levels seen in HCs. The findings implicate a cautionary 
approach to studies of PI-FGID not including a group of RCs. 
Further investigations into subsets and activation status of the 
prolonged alterations of mucosal lymphocyte subsets are war-
ranted and may reveal clues for elucidating the pathogenesis of 
PI-FGID.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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Dizdar et al. Supplementary material 
Histological grading examples 
 
 
Biopsy results were divided into two groups; normal histology (grade H0), mild 
pathology and moderate to severe pathology (grade H1). These biopsies showed 
inflammation with oedema and infiltration of leukocytes and increased number of 
plasma cells in the lamina propria with or without architectural distortion in the form of 
shortening and blunting of intestinal villi. 
 





Figure S1. Grade H0 – normal histology 
Female, 30 years old: Symptom duration 9 months. No signs of mucosal inflammation. 
Giardia trophozoites seen above the mucosa. 
 
 











Dizdar et al. Supplementary material 
Figure S2. Grade H1 – mild pathology 
Female, 47 years old. Symptom duration 8 months. Focal mild active inflammation and 
increased intraepithelial lymphocytes. Giardia not seen above mucosa, nor in stool samples. 
  
 
Figure S3. Grade H1 – moderate to severe pathology 
Female 31 years old. Symptom duration 4 months. Moderate chronic active inflammation and 
villous shortening. Giardia not seen. However, stool samples were positive for giardia. 
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